U.S. patent application number 12/745023 was filed with the patent office on 2011-08-04 for immunoglobulin constructs.
This patent application is currently assigned to Ablynx N.V.. Invention is credited to Guy Hermans, Hilde Adi Pierrette Revets, Michael John Scott Saunders.
Application Number | 20110189203 12/745023 |
Document ID | / |
Family ID | 40377235 |
Filed Date | 2011-08-04 |
United States Patent
Application |
20110189203 |
Kind Code |
A1 |
Hermans; Guy ; et
al. |
August 4, 2011 |
IMMUNOGLOBULIN CONSTRUCTS
Abstract
The present invention relates to protein and polypeptide
constructs that comprise single variable domains that are linked to
an Fc portion. The immunoglobulin constructs comprise two
polypeptide chains in which each polypeptide chain comprises two or
more single variable domains that are linked, usually via a
suitable hinge region or linker, to one or more constant domains
that, together, form an Fc portion. The invention also relates to
polypeptide chains that form part of such constructs and/or that
can be used to form such constructs. The invention further relates
to nucleotide sequences and nucleic acids that encode or can be
used to express such constructs or polypeptide chains; to methods
for producing such constructs and polypeptides chains; to
compositions (and in particular pharmaceutical compositions) that
comprise such constructs or polypeptide chains; and to uses of such
constructs, polypeptide chains or compositions.
Inventors: |
Hermans; Guy; (Merelbeke,
BE) ; Revets; Hilde Adi Pierrette; (Meise, BE)
; Saunders; Michael John Scott; (Brussels, BE) |
Assignee: |
Ablynx N.V.
Ghent-Zwijnaarde
BE
|
Family ID: |
40377235 |
Appl. No.: |
12/745023 |
Filed: |
November 27, 2008 |
PCT Filed: |
November 27, 2008 |
PCT NO: |
PCT/EP08/66368 |
371 Date: |
October 20, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61004332 |
Nov 27, 2007 |
|
|
|
61005265 |
Dec 4, 2007 |
|
|
|
61005324 |
Dec 4, 2007 |
|
|
|
61005331 |
Dec 4, 2007 |
|
|
|
Current U.S.
Class: |
424/174.1 ;
424/130.1; 435/326; 435/69.6; 530/387.1; 536/23.4 |
Current CPC
Class: |
C07K 2317/31 20130101;
C07K 2317/22 20130101; C07K 2317/32 20130101; C07K 2317/52
20130101; C07K 2317/94 20130101; A61K 2039/505 20130101; C07K 16/32
20130101; A61P 1/04 20180101; A61P 29/00 20180101; C07K 16/2863
20130101; C07K 2317/565 20130101; C07K 2319/00 20130101; C07K
16/468 20130101; C07K 2317/76 20130101; A61P 25/00 20180101; A61P
35/00 20180101; A61P 43/00 20180101; A61P 17/06 20180101; C07K
2317/567 20130101; C07K 2317/569 20130101; C07K 2317/64 20130101;
A61P 19/02 20180101; A61P 37/02 20180101; C07K 16/3007 20130101;
A61K 39/3955 20130101 |
Class at
Publication: |
424/174.1 ;
530/387.1; 536/23.4; 435/69.6; 435/326; 424/130.1 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C07K 16/18 20060101 C07K016/18; C07K 16/24 20060101
C07K016/24; C07K 16/28 20060101 C07K016/28; C07H 21/04 20060101
C07H021/04; C12P 21/06 20060101 C12P021/06; C12N 5/16 20060101
C12N005/16; A61P 35/00 20060101 A61P035/00 |
Claims
1. Immunoglobulin construct, comprising an Fc portion that is
linked, optionally via a suitable linker or hinge region, to a pair
of first single variable domains, which are linked, optionally via
a suitable linker, to a pair of second single variable domains,
wherein: both of the first single variable domains are directed
against a first target, antigen epitope, antigenic determinant,
part, domain or subunit; and both of the second single variable
domains are directed against a second target, antigen, epitope,
antigenic determinant, part, domain or subunit.
2. Immunoglobulin construct according to claim 1, in which: both of
the first single variable domains are directed against a first
target or antigen; and both of the second single variable domains
are directed against a second target or antigen different from the
first target or antigen.
3. Immunoglobulin construct according to claim 1, in which: the
first single variable domains and the second single variable
domains are directed against the same target or antigen; both of
the first single variable domains are directed against a first
epitope, antigenic determinant, part, domain or subunit on said
target or antigen; and both of the second single variable domains
are directed against a second epitope, antigenic determinant, part,
domain or subunit on said target or antigen which is the same as
said first epitope, antigenic determinant, part, domain or
subunit.
4. Immunoglobulin construct according to claim 1, in which: the
first single variable domains and the second single variable
domains are directed against the same target or antigen; both of
the first single variable domains are directed against a first
epitope, antigenic determinant, part, domain or subunit on said
target or antigen; and both of the second single variable domains
are directed against a second epitope, antigenic determinant, part,
domain or subunit on said target or antigen which is different from
said first epitope, antigenic determinant, part, domain or
subunit.
5. Immunoglobulin construct according to claim 1, which is directed
against HER-2.
6. Immunoglobulin construct according to claim 5, in which the
first single variable domains are directed against the
Herceptin.RTM. binding site on HER-2 and/or are single variable
domains that are capable of competing with Herceptin.RTM. for
binding to HER-2; and the second single variable domains are
directed against the Omnitarg.RTM. binding site on HER-2 and/or are
single variable domains that are capable of competing with
Omnitarg.RTM. for binding to HER-2 (or vice versa).
7. Immunoglobulin construct according to claim 1, in which: the
first single variable domains and the second single variable
domains are directed against the same target or antigen, which is a
target or antigen that comprises two or more subunits (i.e. a
heteromeric target or antigen); both of the first single variable
domains are directed against a first subunit on said target or
antigen; and both of the second single variable domains are
directed against a second subunit of said target or antigen which
is different from said first subunit.
8. Immunoglobulin construct according to claim 7, which is directed
against a heteromeric receptor.
9. Immunoglobulin construct according to claim 7, which is directed
against a heterodimeric cytokine.
10. Immunoglobulin construct according to claim 9, in which the
first single variable domains are directed against a subunit chosen
from p19, p35 and p28, and the second single variable domains are
directed against a subunit chosen from p40 and EBI3 (or vice
versa)
11. Immunoglobulin construct according to claim 9, which is
directed against IL-23.
12. Immunoglobulin construct according to claim 9, in which the
first single variable domains are directed against IL12p40, and the
second single variable domains are directed against IL23p19 (or
vice versa).
13. Polypeptide, comprising two or three constant domains that are
capable of forming (e.g. with the constant domains of a second such
polypeptide chain) an Fc portion, or that form a monomeric Fc
portion, which is linked, optionally via a suitable linker or hinge
region, to a first single variable domain, which is linked,
optionally via a suitable linker, to a second single variable
domain, wherein: the first single variable domain is directed
against a first target, antigen epitope, antigenic determinant,
part, domain or subunit; and the second single variable domain is
directed against a second target, antigen, epitope, antigenic
determinant, part, domain or subunit.
14. Polypeptide according to claim 13, in which: the first single
variable domain is directed against a first target or antigen; and
the second single variable domain is directed against a second
target or antigen different from the first target or antigen.
15. Polypeptide according to claim 13, in which: the first single
variable domain and the second single variable domain are directed
against the same target or antigen; the first single variable
domain is directed against a first epitope, antigenic determinant,
part, domain or subunit on said target or antigen; and the second
single variable domain is directed against a second epitope,
antigenic determinant, part, domain or subunit on said target or
antigen which is the same as said first epitope, antigenic
determinant, part, domain or subunit.
16. Polypeptide according to claim 13, in which: the first single
variable domain and the second single variable domain are directed
against the same target or antigen; the first single variable
domain is directed against a first epitope, antigenic determinant,
part, domain or subunit on said target or antigen; and the second
single variable domain is directed against a second epitope,
antigenic determinant, part, domain or subunit on said target or
antigen which is different from said first epitope, antigenic
determinant, part, domain or subunit.
17. Polypeptide according to claim 13, which is directed against
HER-2.
18. Polypeptide according to claim 17, in which the first single
variable domain is directed against the Herceptin.RTM. binding site
on HER-2 and/or is a single variable domain that is capable of
competing with Herceptin.RTM. for binding to HER-2; and the second
single variable domain is directed against the Omnitarg.RTM.
binding site on HER-2 and/or is a single variable domains that is
capable of competing with Omnitarg.RTM. for binding to HER-2 (or
vice versa).
19. Polypeptide according to claim 13, in which: the first single
variable domain and the second single variable domain are directed
against the same target or antigen, which is a target or antigen
that comprises two or more subunits (i.e. a heteromeric target or
antigen); the first single variable domain is directed against a
first subunit on said target or antigen; and the second single
variable domain is directed against a second subunit of said target
or antigen which is different from said first subunit.
20. Polypeptide according to claim 19, which is directed against a
heteromeric receptor.
21. Polypeptide according to claim 19, which is directed against a
heterodimeric cytokine.
22. Polypeptide according to claim 21, in which the first single
variable domain is directed against a subunit chosen from p19, p35
and p28, and the second single variable domain is directed against
a subunit chosen from p40 and EBI3 (or vice versa)
23. Polypeptide according to claim 21, which is directed against
IL-23.
24. Polypeptide according to any of claims 21 to 23, in which the
first single variable domain is directed against IL12p40, and the
second single variable domain is directed against IL23p19 (or vice
versa).
25. Nucleotide sequence or nucleic acid that encodes and/or that
can be used to express a polypeptide construct according to claim
1.
26. Method for preparing a polypeptide construct, which method
comprises joining two polypeptides according to claim 13 so as to
form a polypeptide construct.
27. Method for preparing a polypeptide construct, which method
comprises co-expressing, in a suitable host or host organism, two
polypeptides according to claim 13 so as to form a polypeptide
construct.
28. Host or host cell that expresses or is capable of expressing a
polypeptide construct according to claim 1.
29. Method for producing a polypeptide construct, said method
comprising maintaining or cultivating a host or host cell according
to claim 28 under conditions such that said host or host cell
expresses or produces a polypeptide construct, and optionally
further comprising isolating the polypeptide construct so expressed
or produced.
30. Composition comprising at least one polypeptide construct
according to claim 1.
31. Composition according to claim 30, which is a pharmaceutical
composition comprising at least one polypeptide construct and one
or more pharmaceutically acceptable carriers, adjuvants or
excipients.
32. (canceled)
33. Polypeptide construct according to claim 1, which is directed
against HER-2, or pharmaceutical composition comprising such a
polypeptide construct, for the prevention or treatment of
cancer.
34. (canceled)
35. (canceled)
36. (canceled)
37. Method for preventing or treating cancer, which method
comprises administering, to a subject in need of such prevention or
treatment, of a therapeutically active amount of a polypeptide
construct according to claim 1 that is directed against HER-2, or
of a pharmaceutical composition comprising such a polypeptide
construct.
Description
[0001] The present invention relates to protein and polypeptide
constructs that comprise single variable domains that are linked to
an Fc portion.
[0002] The immunoglobulin single variable domains may for example
be a domain antibody (or an immunoglobulin variable domain that is
suitable for use as a domain antibody), a single domain antibody
(or an immunoglobulin variable domain that is suitable for use as a
single domain antibody), a "dAb" (or an immunoglobulin variable
domain that is suitable for use as a dAb) or a Nanobody (as defined
herein, and including but not limited to a V.sub.HH sequence); or
any suitable fragment of any one thereof.
[0003] The invention also relates to polypeptide chains that form
part of such constructs and/or that can be used to form such
constructs.
[0004] The invention further relates to nucleotide sequences and
nucleic acids that encode or can be used to express such constructs
or polypeptide chains; to methods for producing such constructs and
polypeptides chains; to compositions (and in particular
pharmaceutical compositions) that comprise such constructs or
polypeptide chains; and to uses of such constructs, polypeptide
chains or compositions.
[0005] Other aspects, embodiments, uses, applications and
advantages of the invention will become clear from the further
disclosure herein.
[0006] Constructs comprising single variable domains that are
linked to an Fc portion are known. For example, as described in EP
0 698 097 and in Hamers-Casterman et al. (Nature 1993, Jun. 3; 363
(6428): 446-8), the naturally occurring "heavy chain antibodies"
from Camelidae comprise naturally occurring single variable domains
(called "V.sub.HH domains") that are linked via a hinge region to
an Fc portion. Interestingly, as further described in these
references, these heavy chain antibodies lack the C.sub.H1 domain
that is present in conventional 4-chain antibodies, with the
V.sub.HH being directly linked--via the hinge--to the C.sub.H2
domain of the Fc portion.
[0007] EP 0 698 097 and its divisional application EP 1 621 554
also describe that V.sub.HH domains can be linked to a human Fc
portion. Reference is for example also made to WO 04/041862 which
describes a fusion of a Nanobody against human TNF to the C.sub.H1
deleted Fc portion of human IgG1.
[0008] WO 04/068820 describes so-called "dAb's" that are linked to
an effector group. The examples given are constructs that comprise
dAb's linked to the Fc of IgG1.
[0009] The constructs described in EP 1 621 554 and WO 04/068820
comprise two polypeptide chains, in which each polypeptide chain
comprises one single variable domain that is linked, usually via a
suitable hinge region or linker, to two constant domains that, in
the final construct, form the Fc portion. These constructs bind to
the intended antigen via the two antigen-binding sites that are
formed by each of the single variable domains.
[0010] WO 02/056910 describes constructs in which binding domains
that include at least one immunoglobulin variable region
polypeptide are linked, via a suitable linker, to C.sub.H2/C.sub.H3
constant regions. In particular, the C.sub.H2 and C.sub.H3 regions
of human IgG or human IgA are mentioned. The immunoglobulin
variable region polypeptide may be all or a portion or fragment of
heavy chain or light chain V-region, provided it is capable of
specifically binding an antigen. WO 02/056910 further gives
examples of constructs in which the immunoglobulin variable region
polypeptide is comprised of an ScFv fragment. These constructs
therefore comprise two polypeptide chains, in which each
polypeptide chain comprises two variable domains (i.e. a V.sub.H
domain and a V.sub.L domain that together form the ScFv fragment)
that are linked to two constant domains (that together with the
constant domains of the other polypeptide chain form an Fc
portion). However, in these constructs the V.sub.H and V.sub.I,
domains that form the ScFv fragment need to interact so as together
form a single antigen binding site, whereas in the constructs of
the invention, each variable domain is a single variable domain
(meaning that it forms a functional antigen binding unit or site
without requiring interaction with another variable domain).
[0011] It is an object of the invention to provide improved
immunoglobulin constructs. In particular, it is an object of the
invention to provide immunoglobulin constructs that have improved
binding to a desired antigen and/or improved selectivity for a
desired antigen.
[0012] The present invention provides immunoglobulin constructs
that comprise two polypeptide chains (each, a "polypeptide chain of
the invention"), in which each polypeptide chain comprises two or
more single variable domains that are linked, usually via a
suitable hinge region or linker, to one or more constant domains
that, in the final construct, together form an Fc portion.
[0013] Thus, the constructs provided by the invention (which are
also referred to herein as "constructs of the invention") generally
comprise an Fc portion (as defined herein) in which each of the two
polypeptide chains that form the Fc portion is linked, optionally
via a suitable linker or hinge region, to two or more single
variable domains (also as defined herein). Such constructs may for
example be as described in EP 1 621 554 or WO 02/056910, but with
one or more additional single variable domains linked to each
single variable domain that is already present in the constructs
described in these references.
[0014] The polypeptide chains of the invention, and their use in
forming the constructs of the invention, form further aspects of
the invention. Also, in one specific aspect of the invention, as
further described herein, these polypeptide chains of the invention
may also be used as such (i.e. without interaction with another
polypeptide chain and/or not as part of a construct of the
invention).
[0015] Preferably, in the constructs of the invention, each
polypeptide chain of the invention comprises two or three single
variable domains, and more preferably only two single variable
domains. In other words, the constructs of the invention preferably
comprise a total of six single variable domains (i.e. three in each
polypeptide chain) and more preferably a total of four single
variable domains (i.e. two in each polypeptide chain).
[0016] Also, each polypeptide chain of the invention will usually
comprise either two constant domains (for example, in case of an Fc
portion that is derived from IgG, IgA or IgD) or three constant
domains (for example, in ease of an Fc portion that is derived from
IgM or IgE), such that, in the final construct, the constant
domains of the two polypeptide chains form an Fc portion, for
example an Fc portion that is derived from IgG (e.g. IgG1, IgG2,
IgG3 or IgG4), IgA, IgD, IgE or IgM, or a variant, analog, mutant,
part or fragment thereof (including chimeric Fc portions), that may
or may not have effector functions, as further described
herein.
[0017] For the sake of convenience, and as these constructs are
generally preferred in practice, the invention will now be
described in more detail with reference to constructs that comprise
a total of four single variable domains (i.e. two in each
polypeptide chain) and four constant domains (i.e. two in each
polypeptide chain), in which the variable domains are linked to
each other via a suitable linker and are linked to the constant
domains via a suitable linker or hinge region. However, it will be
clear to the skilled person that the teaching of the present
invention can equally be applied to constructs of the invention
that comprise six or even more single variable domains (i.e. three
or more variable domains in each polypeptide chain), and/or that
comprise six constant domains (for example, in case of an Fc
portion that is derived from IgM or IgE), and/or in which the
constant domains are directly linked to each other and/or directly
linked to the constant domains (for example, when the Fc portion is
derived from IgE, a hinge region between the Fc portion and the
variable domains may not be required).
[0018] In these preferred, but non-limiting constructs of the
invention, each polypeptide chain of the invention comprises two
constant domains that are capable, together with the constant
domains that are present in the other polypeptide chain that forms
part of the construct, to form an Fc portion (as defined herein).
These constant domains are linked (optionally via a suitable linker
or hinge region) to a "first" single variable domain, which first
single variable domain is linked (again optionally via a suitable
linker) to a "second" single variable domain (which may in turn be
linked, again optionally via a suitable linker, to a "third" single
variable domain, and so forth).
[0019] Constructs of the invention with four single variable
domains and four constant domains (for example forming an Fc
portion derived from an IgG or IgA, or an analog, mutant or variant
thereof) are schematically shown in the non-limiting FIG. 1. The
constructs comprise two polypeptide chains (1) and (2), which each
comprise two constant domains (7) and (8), a "first" single
variable domain (3) and a "second" single variable domain (4). The
first single variable domain (3) is linked, optionally via a
suitable linker (5), to the second single variable domain (4), and
is also linked to the constant domains, optionally (and usually)
via a suitable linker or hinge region (6). The constant domains (7)
and (8) of the polypeptide chain (1) and the corresponding constant
domains (7) and (8) of the polypeptide chain (2) together form the
Fc portion (9).
[0020] Constructs of the invention with four single variable
domains and six constant domains (for example forming an Fc portion
derived from IgE, or an analog, mutant or variant thereof) are
schematically shown in the non-limiting FIG. 2. The constructs
comprise two polypeptide chains (1) and (2), which each comprise
three constant domains (7), (8) and (10), a "first" single variable
domain (3) and a "second" single variable domain (4). The first
single variable domain (3) is linked, optionally via a suitable
linker (5), to the second single variable domain (4), and is also
linked to the constant domains, optionally (and usually) via a
suitable linker or hinge region (6). The constant domains (7), (8)
and (10) of the polypeptide chain (1) and the corresponding
constant domains (7), (8) and (10) of the polypeptide chain (2)
together form the Fc portion (9).
[0021] An example of a construct of the invention with more than
four single variable domains is schematically shown in the
non-limiting FIG. 3. This FIG. 3 shows a constructs of the
invention with six single variable domains and four constant
domains (for example forming an Fc portion derived from an IgG or
IgA, or an analog, mutant or variant thereof). The construct
comprise two polypeptide chains (1) and (2), which each comprise
two constant domains (7) and (8), a "first" single variable domain
(3), a "second" single variable domain (4) and a "third" single
variable domain (11). The first single variable domain (3) is
linked, optionally via a suitable linker (5), to the second single
variable domain (4), and is also linked to the constant domains,
optionally (and usually) via a suitable linker or hinge region (6).
The third first single variable domain (11) is linked, optionally
via a suitable linker (12), to the second single variable domain
(4). The constant domains (7) and (8) of the polypeptide chain (1)
and the corresponding constant domains (7) and (8) of the
polypeptide chain (2) together form the Fc portion (9). In
constructs with more than six single variable domains, each chain
(1) and (2) can contain one or more additional single variable
domains (not shown), which can be linked to the third single
variable domain (11) and to each other, again optionally via
suitable linkers.
[0022] FIG. 4 schematically shows a non-limiting example of a
polypeptide of the invention, comprising two single variable
domains and two constant domains. The polypeptide comprises two
constant domains (7) and (8), a "first" single variable domain (3)
and a "second" single variable domain (4). The first single
variable domain (3) is linked, optionally via a suitable linker
(5), to the second single variable domain (4), and is also linked
to the constant domains, optionally (and usually) via a suitable
linker or hinge region (6). As further described herein, such a
polypeptide chain may be used to form a construct of the invention
(i.e. with another polypeptide chain of the invention), but may
also be used as such (i.e. without interaction with another
polypeptide chain of the invention), for example when the Fc chain
that is formed by the constant domains is monomeric (i.e. non
self-associating).
[0023] In the constructs of the invention, all of the single
variable domains that are present in the construct may each be
directed against a different target, antigen, antigenic determinant
or epitope. However, this is generally less preferred. Preferably,
both of the "first" single variable domains that are present in
each of the polypeptide chain are directed against the same target
or antigen, and both of the "second" single variable domains that
are present in each of the polypeptide chain are directed against
the same target or antigen (and so on for the "third" and further
single variable domains).
[0024] In this aspect of the invention, the first single variable
domains and second single variable domains may be directed against
a different target or antigen (such that the constructs of the
invention are capable of simultaneously binding to two different
targets or antigens); or may be directed against the same target or
antigen (such that all single variable domains present in the
construct are capable of binding to the same target or
antigen).
[0025] As further described herein, when two or more single
variable domains in a construct of the invention are capable of
binding to the same target or antigen, they may bind to the same
epitope, antigenic determinant, part, domain or subunit of the
target or antigen, or to different epitopes, antigenic
determinants, parts, domains or subunits of the target or antigen.
For example, when the first and second binding domains are capable
of binding to different targets or antigens, usually both of the
first single variable domains will bind to the same epitope,
antigenic determinant, part, domain or subunit of the first target
or antigen, and both the second single variable domains will bind
to the same epitope, antigenic determinant, part, domain or subunit
of the second target or antigen (although the invention in its
broadest sense is not limited thereto).
[0026] Also, when the first and second binding domains are capable
of binding to the same target or antigen, usually both of the first
single variable domains will bind to the same epitope, antigenic
determinant, part, domain or subunit of the target or antigen, and
both of the second single variable domains will bind to the same
epitope, antigenic determinant, part, domain or subunit of the
target or antigen (although the invention in its broadest sense is
again not limited thereto, and for example also comprises
constructs in which each of the single variable domains can bind to
a different epitope, antigenic determinant, part, domain or subunit
of the target or antigen). In the latter case, again as further
described herein, the first single variable domains and the second
single variable domains may bind to the same epitope, antigenic
determinant, part, domain or subunit on the target or antigen, or
may bind to different epitopes, antigenic determinants, parts,
domains or subunits of the target or antigen.
[0027] Thus, in a preferred but non-limiting aspect of the
invention, the constructs of the invention comprise an Fc portion
that is linked (optionally via a suitable linker or hinge region)
to a pair of first single variable domains (i.e. one linked to each
polypeptide chain that forms the Fc portion, as further described
herein), which are linked (optionally via a suitable linker) to a
pair of second single variable domains, wherein the constructs and
the single variable domains present therein are such that: [0028]
both of the first single variable domains are directed against a
first target, antigen epitope, antigenic determinant, part, domain
or subunit; and [0029] both of the second single variable domains
are directed against a second target, antigen, epitope, antigenic
determinant, part, domain or subunit.
[0030] For example, in one aspect of the invention, the constructs
of the invention and the single variable domains present therein
may be such that: [0031] both of the first single variable domains
are directed against a first target or antigen; and [0032] both of
the second single variable domains are directed against a second
target or antigen different from the first target or antigen.
[0033] As further described herein, such constructs of the
invention may be capable of binding two different targets or
antigens simultaneously.
[0034] In another aspect of the invention, the constructs of the
invention and the single variable domains present therein may be
such that: [0035] the first single variable domains and the second
single variable domains are directed against the same target or
antigen; [0036] both of the first single variable domains are
directed against a first epitope, antigenic determinant, part,
domain or subunit on said target or antigen; and [0037] both of the
second single variable domains are directed against a second
epitope, antigenic determinant, part, domain or subunit on said
target or antigen which is the same as said first epitope,
antigenic determinant, part, domain or subunit.
[0038] As further described herein, such constructs of the
invention may be capable of binding to the relevant target or
antigen with greater avidity than a comparable construct that
comprises only one pair of single variable domains (e.g. as
described in EP 1 621 554 or WO 04/068820)
[0039] In yet another aspect of the invention, the constructs of
the invention and the single variable domains present therein may
be such that: [0040] the first single variable domains and the
second single variable domains are directed against the same target
or antigen; [0041] both of the first single variable domains are
directed against a first epitope, antigenic determinant, part,
domain or subunit on said target or antigen; and [0042] both of the
second single variable domains are directed against a second
epitope, antigenic determinant, part, domain or subunit on said
target or antigen which is different from said first epitope,
antigenic determinant, part, domain or subunit.
[0043] Again, as further described herein, such constructs of the
invention may be capable of binding to the relevant target or
antigen with greater avidity than a comparable construct that
comprises only one pair of single variable domains (e.g. as
described in EP 1 621 554 or WO 04/068820).
[0044] For example, in such constructs, the first variable domains
may be directed against an "interaction site" on the target or
antigen (i.e. a site for ligand binding, a catalytic site, a
cleavage site, a site for allosteric interaction, a site involved
in homodimerization or heterodimerization of the target or antigen;
or any other site, epitope, antigenic determinant, part, domain or
stretch of amino acid residues on the target or antigen that is
involved in a biological action or mechanism of the target or
antigen); and the second single variable domains may be directed
against another site, epitope, antigenic determinant, part, domain
or stretch of amino acid residues on the target or antigen that is
not an interaction site (or visa versa). A non-limiting example of
such a construct is given in FIG. 9A and SEQ ID NO: 9, which
constructs comprises one Nanobody (121A2 p19+) that can bind to the
p19 subunit of IL-23 and that can modulate (and in particular,
reduce) binding of IL-23 to its receptor, and one Nanobody (81 G2
p19-) that can bind to the p19 subunit of IL-23 but that does not
modulate binding of IL-23 to its receptor.
[0045] Alternatively, the first variable domains may be directed
against an interaction site on the target or antigen, and the
second variable domains may be directed against different
interaction site on the target or antigen. Besides binding to the
target or antigen with increased avidity, such constructs have the
further advantage that they are capable of modulating (as defined
herein) two different mechanisms of action of the target or antigen
simultaneously.
[0046] For example, in a specific, but non-limiting aspect, a
construct of the invention may be directed against HER-2. For
example, in a construct of the invention that is directed against
HER-2 [0047] the first single variable domains may be directed
against the Herceptin.RTM. binding site on HER-2 (and in particular
against domain IV of HER-2, and more in particular against the
C-terminus of domain IV of HER-2) and/or be single variable domains
that are capable of competing with Herceptin.RTM. for binding to
HER-2; and the second single variable domains may be directed
against another site, epitope, antigenic determinant, part, domain
or stretch of amino acid residues on HER-2 (or visa versa). These
constructs are generally such that they are capable of modulating
HER-2 via the mechanism of action of Herceptin.RTM., and in
addition may have one or more effector functions (depending on the
Fc portion used); [0048] the first single variable domains may be
directed against the Omnitarg.RTM. binding site on HER-2 (and in
particular against domain II of HER-2, and more in particular
against the middle of domain II of HER-2) and/or be single variable
domains that are capable of competing with Omnitarg.RTM. for
binding to HER-2; and the second single variable domains may be
directed against another site, epitope, antigenic determinant,
part, domain or stretch of amino acid residues on HER-2 (or visa
versa). These constructs are generally such that they are capable
of modulating TIER-2 via the mechanism of action of Omnitarg.RTM.,
and in addition may have one or more effector functions (depending
on the Fc portion used); [0049] the first single variable domains
may be directed against the Herceptin.RTM. binding site on HER-2
(and in particular against domain IV of HER-2, and more in
particular against the C-terminus of domain IV of HER-2) and/or be
single variable domains that are capable of competing with
Herceptin.RTM. for binding to HER-2; and the second single variable
domains may be directed against the Omnitarg.RTM. binding site on
HER-2 (and in particular against domain II of HER-2, and more in
particular against the middle of domain II of HER-2) and/or be
single variable domains that are capable of competing with
Omnitarg.RTM. for binding to HER-2. Such a construct is further
preferably such that it is capable of (simultaneously) binding to
both the Omnitarg.RTM. binding site on HER-2 (and in particular
against domain II of HER-2, and more in particular against the
middle of domain II of HER-2) as well as the Herceptin.RTM. binding
site on HER-2 (and in particular against domain IV of HER-2, and
more in particular against the C-terminus of domain IV of HER-2),
most preferably so as to allow binding with increased avidity and
also intramolecular binding and/or recognition. These constructs
are preferably further such that they are capable, as a single
construct, to modulate HER-2 via both the mechanism of action of
Herceptin.RTM. as well as the mechanism of action of Omnitarg.RTM.,
and in addition may have one or more effector functions (depending
on the Fc portion used).
[0050] For examples of single variable domains that can be used in
such constructs, reference is made to the co-pending International
patent application of Ablynx N. V. with the same filing date as the
present application, entitled "Amino acid sequences directed
against HER2 and polypeptides comprising the same for the treatment
of cancers and/or tumors". Some non-limiting examples of such
constructs are given in SEQ ID NO's: 1 to 8 and FIGS. 5 to 8.
[0051] Also, constructs of the invention that are directed against
tumor cells or tumor antigens (such as HER-2) may comprise an Fc
portion that is derived from IgG (e.g. an IgG1, IgG2, IgG3 or IgG4)
or IgA (or, less preferred, even IgM, IgD); but according to one
specific aspect of the invention comprise an "IgE-derived Fc
portion" (i.e. an Fc portion that is derived from IgE) as described
in the co-pending International patent application of Ablynx N. V.
entitled "Constructs comprising single variable domains and an Fc
portion derived from IgE", which has the same filing date as the
present application.
[0052] In yet another aspect of the invention, the constructs of
the invention and the single variable domains present therein may
be such that: [0053] the first single variable domains and the
second single variable domains are directed against the same target
or antigen, which is a target or antigen that comprises two or more
subunits (i.e. a heteromeric target or antigen); [0054] both of the
first single variable domains are directed against a first subunit
on said target or antigen; and [0055] both of the second single
variable domains are directed against a second subunit of said
target or antigen which is different from said first subunit.
[0056] As further described herein, such constructs of the
invention may not only be capable of binding to the relevant target
or antigen with greater avidity than a comparable construct that
comprises only one pair of single variable domains (e.g. as
generally described in EP 1 621 554 or WO 04/068820, without
reference to HER-2 as a possible target or antigen), but may also
have improved selectivity, in particular when either the first
and/or the second subunit is common between different heteromeric
targets and antigens, as is for example the case for heterodimeric
cytokines such as IL-12, IL-23, IL-27 and IL-35 (see Collson et
al., Nature, Vol. 450, 22 Nov. 2007, 566), which share common
subunits; and also for heteromeric (such as heterodimeric or
heterotrimeric) receptors, such as the receptors for IL-12, IL-23
and IL-27, which share common receptor chains. Reference is made to
the co-pending International patent application entitled "Amino
acid sequences directed against heterodimeric cytokines and/or
their receptors and polypeptides comprising the same" of Ablynx N.
V., which has the same filing date as the present application.
[0057] Accordingly, in a specific, but non-limiting aspect, a
construct of the invention may be directed against a heteromeric
cytokine, and in particular against a heterodimeric cytokine of the
IL-12 family, such as IL-12, IL-23, IL-27 or IL-35. For example,
such a construct of the invention may comprise first single
variable domains that are directed against IL12p40, IL12p35,
IL23p19, EBI3 or IL27p28, and second single variable domains that
are directed against the same subunit or against another subunit
that is present in a heteromeric cytokine, and in particular
against a heterodimeric cytokine of the IL-12 family.
[0058] When the first and single variable domains are directed
against the same subunit, they may for example: [0059] be directed
against p19 (in which case the construct may be selective for IL-23
compared to IL-12, IL-27 and IL-35). Such a construct may for
example at least comprise, in each polypeptide chain, (i) two or
more single variable domains that are capable of modulating binding
of IL-23 to its receptor; (ii) two or more single variable domains
that can bind to p19 but that are not capable of modulating binding
of IL-23 to its receptor; or (iii) at least one single variable
domain that is capable of modulating binding of IL-23 to its
receptor and at least one single variable domains that can bind to
p19 but that is not capable of modulating binding of IL-23 to its
receptor; [0060] be directed against p35 (in which case the
construct may be selective for IL-12 and IL-35 compared to IL-23
and IL-27). Such a construct may for example at least comprise, in
each polypeptide chain, (i) two or more single variable domains
that are capable of modulating binding of IL-12 and/or IL-35 to
their respective receptors; (ii) two or more single variable
domains that can bind to p35 but that are not capable of modulating
binding of IL-12 and/or IL-35 to their respective receptors; or
(iii) at least one single variable domain that is capable of
modulating binding of IL-12 and/or IL-35 to their respective
receptors and at least one single variable domains that can bind to
p35 but that is not capable of modulating binding of IL-12 and/or
IL-35 to their respective receptors; [0061] be directed against p28
(in which case the construct may be selective for IL-27 compared to
IL-12. IL-23 and IL-35). Such a construct may for example at least
comprise, in each polypeptide chain, (i) two or more single
variable domains that are capable of modulating binding of IL-27 to
its receptor; (ii) two or more single variable domains that can
bind to p28 but that are not capable of modulating binding of IL-27
to its receptor; or (iii) at least one single variable domain that
is capable of modulating binding of IL-27 to its receptor and at
least one single variable domains that can bind to p28 but that is
not capable of modulating binding of IL-27 to its receptor; [0062]
be directed against p40 (in which case the construct may be
selective for IL-12 and IL-23 compared to IL-27 and IL-35). Such a
construct may for example at least comprise, in each polypeptide
chain, (i) two or more single variable domains that are capable of
modulating binding of IL-12 and/or IL-23 to their respective
receptors; (ii) two or more single variable domains that can bind
to p40 but that are not capable of modulating binding of IL-12
and/or IL-23 to their respective receptors; or (iii) at least one
single variable domain that is capable of modulating binding of
IL-12 and/or IL-23 to their respective receptors and at least one
single variable domains that can bind to p40 but that is not
capable of modulating binding of IL-12 and/or IL-23 to their
respective receptors; [0063] be directed against EBI3 (in which
case the construct may be selective for IL-27 and IL-35 compared to
IL-12 and IL-23). Such a construct may for example at least
comprise, in each polypeptide chain, (i) two or more single
variable domains that are capable of modulating binding of IL-27
and/or IL-35 to their respective receptors; (ii) two or more single
variable domains that can bind to EBI3 but that are not capable of
modulating binding of IL-27 and/or IL-35 to their respective
receptors; or (iii) at least one single variable domain that is
capable of modulating binding of IL-27 and/or IL-35 to their
respective receptors and at least one single variable domains that
can bind to EBI3 but that is not capable of modulating binding of
IL-27 and/or IL-35 to their respective receptors; and such
constructs may bind with higher avidity to the relevant
heterodimeric cytokine than a comparable construct that comprises
only one pair of single variable domains (e.g. as generally
described in EP 1 621 554 or WO 04/068820, without reference to
heterodimeric cytokines as potential targets or antigens). A
non-limiting example of such a construct is given in FIG. 9A and
SEQ ID NO: 9.
[0064] In a particularly preferred aspect, the first and second
single variable domains are directed against different subunits.
For example, the first single variable domains may be directed
against a subunit chosen from p19, p35 and p28, and the second
single variable domains may be directed against a subunit chosen
from p40 and EBI3 (or visa versa). For example: [0065] a construct
of the invention that is directed against IL-12 may comprise first
single variable domains that are directed against IL12p40, and
second single variable domains that are directed against IL12p35
(or visa-versa); [0066] a construct of the invention that is
directed against IL-23 may comprise first single variable domains
that are directed against IL12p40, and second single variable
domains that are directed against IL23p19 (or visa-versa); [0067] a
construct of the invention that is directed against IL-27 may
comprise first single variable domains that are directed against
EBI3, and second single variable domains that are directed against
IL27p28 (or visa-versa); [0068] a construct of the invention that
is directed against IL-35 may comprise first single variable
domains that are directed against EBI3, and second single variable
domains that are directed against IL12p35 (or visa-versa); and such
constructs may be more selective for the relevant heterodimeric
cytokine than a comparable construct that comprises only one pair
of single variable domains (e.g. as described in EP 1 621 554 or WO
04/068820) or that comprises two or more pairs of single variable
domains against the same subunit. Non-limiting examples of such a
construct are given in FIGS. 9B and 9C and in SEQ ID NO's: 10 and
11.
[0069] As further described herein, such constructs (and in
particular, the linkers present therein) are further preferably
such that they are capable of binding to both of the subunits
against which they are directed, more preferably essentially
simultaneously so as to allow binding with increased avidity and
specificity.
[0070] For examples of single variable domains that can be used in
such constructs against heterodimeric cytokines (as well as
bispecific combinations of such single variable domains that are
directed against different subunits), reference is made to the
co-pending International patent application of Ablynx N. V.
entitled "Amino acid sequences directed against heterodimeric
cytokines and/or their receptors and polypeptides comprising the
same" of Ablynx N. V., which has the same filing date as the
present application.
[0071] The above constructs are generally capable of modulating the
heterodimeric cytokine(s) against which they are directed. Also,
depending on the Fc portion present (as further described herein),
the above constructs against heterodimeric cytokines may or may not
have one or more effector functions.
[0072] In the polypeptide chains that form the constructs of the
invention, the constant domains are suitably linked to the single
variable domains, either directly (which is less preferred), via a
suitable hinge region or linker (which is most preferred), or even
(although much less preferred) via a suitable constant domain (such
as a C.sub..alpha.1, C.sub..delta.1, C.sub..mu.1 or preferably
C.sub.H1 or C.sub..epsilon.1 domain, which may in turn be linked to
the Fc portion via a suitable linker).
[0073] The hinge region or linker may be any suitable hinge region
or linker, and suitable hinge regions and linkers, which will
usually comprise or essentially consist of a suitable amino acid
sequence, will be clear to the skilled person based on the
disclosure herein. Some preferred, but non-limiting examples
include the hinge regions that naturally occur in immunoglobulins
(such as the hinge region of IgG's or the hinge region from Camelid
heavy chain antibodies, see for example EP 0 698 097 or the linkers
described in WO 96/34103), suitable analogs, variants, homologs,
parts or fragments thereof (including synthetic or semi-synthetic
analogs, variants, homologs, parts or fragments, for example hinge
regions that have been engineered so as not to contain cysteine
residues, see for example WO 07/085,814), as well as the synthetic
and semi-synthetic linkers mentioned in WO 04/068820 and WO
02/056910, as well as the linkers that are mentioned in WO 06/122
825 for linking Nanobodies in multivalent Nanobody constructs.
Also, a naturally occurring CJ domain or a suitable variant thereof
may be used as (or instead of) a hinge region. By means of
non-limiting example, a nucleotide sequence encoding a hinge from a
Camelid heavy chain antibody (see EP 0 698 097) is given in Table 1
(SEQ ID NO: 14) below.
[0074] In the polypeptide chains that form the constructs of the
invention, the first and second (and optionally third and further)
single variable domains are also suitably linked to each other,
either directly (which is less preferred) or via a suitable hinge
regions or linkers (which is most preferred), or even (although
much less preferred) via a suitable constant domain.
[0075] Suitable linkers will be clear to the skilled person based
on the disclosure herein, and include the linkers and hinge regions
mentioned above for linking the single variable domains to the
constant domains, the synthetic and semi-synthetic linkers
mentioned in WO 04/068820 and WO 02/056910, the linkers that are
mentioned in WO 06/122 825 for linking Nanobodies in multivalent
Nanobody constructs, as well as the spacers and linkers that are
used in the art to link antibody fragments or antibody domains.
These include the linkers mentioned in the general background art
cited herein, as well as for example linkers that are used in the
art to construct diabodies or ScFv fragments.
[0076] For example, the linker may be a suitable amino acid
sequence, and in particular amino acid sequences of between 1 and
60, preferably between 15 and 50, such as between 20 and 40 amino
acid residues, such as about 25, 30 or 40 amino acid residues
(depending on the amino acid composition of the linker). Some
preferred examples of such amino acid sequences include gly-ser
linkers, for example of the type (gly.sub.xser.sub.y).sub.z, such
as (for example (gly.sub.4ser).sub.3 or (gly.sub.3ser.sub.2).sub.3,
as described in WO 99/42077 and the GS30, GS15, GS9 and GS7 linkers
described in the applications by Ablynx mentioned herein (see for
example WO 06/040153 and WO 06/122825), as well as hinge-like
regions, such as the hinge regions of naturally occurring heavy
chain antibodies or similar sequences (such as described in WO
94/04678). Some other particularly preferred linkers are the
linkers GS9 (SEQ ID NO: 84 in WO 06/122825), and in particular the
linkers GS30 (SEQ ID NO: 85 in WO 06/122825) and GS 35 (used in the
constructs of SEQ ID NO's: 1 to 8).
[0077] Generally, the constructs of the invention, and in
particular the linkers that link the first and second single
variable domains, are preferably such that both the first single
variable domains and the second single variable domains are capable
of binding to their intended or respective target, antigen,
epitope, antigenic determinant, part, domain or subunit, more
preferably essentially simultaneously, so as to allow binding with
higher avidity (and, where relevant, higher specificity or with
other advantages that can be obtained through the use of the
constructs of the invention). The skilled person will be able to
choose suitable linkers for this purpose, optionally using in
silico techniques for molecular modelling and/or a limited degree
of experimentation. For an example of such in silico techniques for
determining optimal linker length and design, reference is for
example made to the co-pending International patent application of
Ablynx N. V. with the same filing date as the present application,
entitled "Amino acid sequences directed against HER2 and
polypeptides comprising the same for the treatment of cancers
and/or tumors" (see Example 19).
[0078] In further aspects, the invention relates to the polypeptide
chains of the invention, and to nucleic acids encoding the same.
Such polypeptide chains of the invention may further be as
described herein for the construct of the invention, albeit that
they consist of a single polypeptide chain with two or more single
variable domains and one or more (such as two or three) constant
domains that are capable (together with the constant domains of
another polypeptide chain of the invention, to form an Fc portion
(as further described herein).
[0079] For example, such polypeptide chains may: [0080] comprise a
first single variable domain that is directed against a first
target, antigen epitope, antigenic determinant, part, domain or
subunit; and a second single variable domain that is directed
against a second target, antigen, epitope, antigenic determinant,
part, domain or subunit; [0081] comprise a first single variable
domain that is directed against a first target or antigen; and a
second single variable domain that is directed against a second
target or antigen different from the first target or antigen;
[0082] comprise a first single variable domain that is directed
against a first epitope, antigenic determinant, part, domain or
subunit on a target or antigen, and a second single variable domain
that is directed against the same epitope, antigenic determinant,
part, domain or subunit of said target or antigen; [0083] comprise
a first single variable domain that is directed against a first
target or antigen, and a second single variable domain that is
directed against the same target or antigen, but against a
different epitope, antigenic determinant, part, domain or subunit
of said target or antigen; [0084] comprise a first single variable
domain that is directed against an interaction site (as described
herein) on a target or antigen, and a second single variable domain
that is directed against another site, epitope, antigenic
determinant, part or domain of said target or antigen that is not
an interaction site (or visa versa). Such a polypeptide chain may
for example be directed against HER-2, and may then be as described
herein for the anti-HER-2 constructs of the invention (but
consisting of a single polypeptide chain); [0085] comprise a first
single variable domain that is directed against an interaction site
(as described herein) on a target or antigen, and a second single
variable domain that is directed against another interaction site
of said target or antigen. Such a polypeptide chain may for example
be directed against HER-2, and may then be as described herein for
the anti-HER-2 constructs of the invention (but consisting of a
single polypeptide chain); [0086] comprise a first single variable
domain that is directed against a first subunit of a heterodimeric
target or antigen, and a second single variable domain that is
directed against the same subunit of said target or antigen. Such a
polypeptide chain may for example be directed against a
heterodimeric cytokine, and may then be as described herein for the
constructs of the invention that are directed against heterodimeric
cytokine (but consisting of a single polypeptide chain); [0087]
comprise a first single variable domain that is directed against a
first subunit of a heterodimeric target or antigen, and a second
single variable domain that is directed against a different subunit
of said target or antigen. Such a polypeptide chain may for example
be directed against a heterodimeric cytokine, and may then be as
described herein for the constructs of the invention that are
directed against heterodimeric cytokine (but consisting of a single
polypeptide chain).
[0088] The polypeptide chains of the invention will usually be used
as part of, and/or to form, a construct of the invention, as
further described herein. However, one specific, but non-limiting,
aspect, the constant domains used in a polypeptide chain of the
invention may be such that they allow the polypeptide chain of the
invention to be used (i.e. for antigen-binding, for example for
therapeutic purposes) as such, i.e. without forming part of a
construct of the invention. Generally, according to this aspect of
the invention, the constant domains may be naturally occurring,
synthetic or semisynthetic analogs, variants, parts or fragments of
constant domains that, when combined in a polypeptide chain of the
invention, confer upon the polypeptide chain a reduced (or
essentially no) tendency to self-associate into dimmers (i.e.
compared to the constant domains that naturally occur in the native
Fc portion). Such monomeric (i.e. not self-associating) Fc chain
variants, or fragments thereof, will be clear to the skilled
person. For example, Helm et al. (J Biol Chem 1996 271 7494),
describe monomeric Fc.epsilon. chain variants that can be used in
the polypeptide chains of the invention.
[0089] Also, such monomeric Fc chain variants are preferably such
that they are still capable of binding to the complement or the
relevant Fc receptor(s) (depending on the Fc portion from which
they are derived), and/or such that they still have some or all of
the effector functions of the Fc portion from which they are
derived (or at a reduced level still suitable for the intended
use). Alternatively, in such a polypeptide chain of the invention,
the monomeric Fc chain may be used to confer increased half-life
upon the polypeptide chain, in which case the monomeric Fc chain
may also have no or essentially no effector functions.
[0090] When two polypeptide chains of the invention form a
construct of the invention, in practice, the first single variable
domains will be essentially the same (i.e. be comprised of
essentially the same amino acid sequence) in both polypeptide
chains that form the construct of the invention, and the second
single variable domain will be essentially the same in both
polypeptide chains that form the construct of the invention
(although the invention in its broadest sense is not limited
thereto). Also, usually, in the practice of the invention, the
constant domains that are present in both of the polypeptide chains
that form the construct of the invention will be essentially the
same (i.e. be comprised of essentially the same amino acid
sequence). Thus, usually, both polypeptide chains that form the
construct of the invention will comprise essentially the same
first, second (and optionally third and further) single variable
domains and essentially the same constant domains, so that the
constructs of the invention will usually be comprised of two
polypeptide chains that have essentially the same (variable and
constant) domains and thus essentially the same sequence. However,
the invention in its broadest sense is not limited thereto, and for
example also comprises constructs in which either or both of the
first and/or the second (and/or optionally the third or further)
variable domains are not the same in the two polypeptide chains
that from the construct of the invention; as well as constructs in
which the two polypeptide chains that form the construct of the
invention comprise different hinge regions or linkers; and even
constructs in which the two polypeptide chains that form the
construct of the invention comprise different constant domains (as
long as the constant domains of the two polypeptide chains are
still capable of forming an Fc portion, as defined herein).
[0091] Thus, in another aspect, the invention relates to an
immunoglobulin construct is directed against an intended or desired
antigen, which immunoglobulin construct comprises an Fc portion and
at least four (such as six and preferably four) single variable
domains, which immunoglobulin construct is capable of binding to
the desired or intended antigen with at least four (such as all six
or all four) single variable domains.
[0092] According to this preferred but non-limiting aspect, when
the single variable domains present in the construct are directed
against the same target or antigen, they may be directed against
the same antigenic determinant, epitope, part or domain on the
target (in particular, for example, when the target is a multimeric
target, so that the same antigenic determinant, epitope, part or
domain occurs multiple times in the multimer), against different
antigenic determinants, epitopes, parts or domains on the target,
or (when the target is a heteromeric protein comprising two or more
different subunits) against different subunits of the target.
[0093] Thus, according to this preferred but non-limiting aspect
aspect, a construct of the invention that is directed against a
desired or intended target or antigen may be comprised of two
polypeptide chains, in which each polypeptide chain comprises one
or more (and usually two or three) constant domains (that are
capable, together with the constant domains that are present in the
other polypeptide chain, to form an Fc portion), that is linked
(optionally via a suitable linker or hinge region) to a "first"
single variable domain that is directed against a first epitope,
antigenic determinant, part, domain or subunit of the target or
antigen, which first single variable domain is linked (again
optionally via a suitable linker) to a "second" single variable
domain that is directed against a second epitope, antigenic
determinant, part, domain or subunit of the target or antigen
(which may in turn be linked, again optionally via a suitable
linker, to a "third" single variable domain that is directed
against a third epitope, antigenic determinant, part, domain or
subunit of the target or antigen, and so forth); in which the first
and second (and optionally third and further) epitope, antigenic
determinant, part, domain or subunit may be the same or
different.
[0094] When the first and second (and optionally third or further)
single variable domains are directed against the same epitope,
antigenic determinant, part, domain or subunit, they may have
essentially the same sequence (which will usually be preferred in
practice) or have different sequences. When the first and second
(and optionally third or further) single variable domains are
directed against different epitopes, antigenic determinants, parts,
domains or subunits, they will as a rule have different
sequences.
[0095] Also, again, in this preferred but non-limiting aspect, the
first single variable domain will preferably be the essentially
same (i.e. be comprised of essentially the same amino acid
sequence) in both polypeptide chains that form the construct of the
invention, the second single variable domain will preferably be
essentially the same in both polypeptide chains that form the
construct of the invention, and the constant domains will
preferably be essentially the same in both polypeptide chains that
form the construct of the invention (so that, again, the constructs
of the invention will be comprised of two polypeptide chains that
have essentially the same (variable and constant) domains and more
in particular essentially the same sequence).
[0096] In one particularly preferred but non-limiting aspect of the
invention, the constructs of the invention are directed towards a
multimeric target or antigen (such as a dimeric target or trimeric
target), and the first and second (and optionally third or further)
single variable domains are directed against the same epitope,
antigenic determinant, part or domain, and preferably have
essentially the same sequence.
[0097] In another particularly preferred but non-limiting aspect of
the invention, the constructs of the invention are directed towards
a heteromeric target or antigen (for example comprised of two or
three different subunits), and the first single variable domain is
directed against a first subunit of the target or antigen and the
second single variable domain is directed against a second subunit
of the target or antigen.
[0098] In one highly specific aspect of the invention, the first
single variable domains may be directed against different antigenic
determinants, epitopes, parts or domains or subunits of the same
target, and the second and further single variable domains may or
may not be present. When the second and further single variable
domains are not present, the constructs of this particular aspect
of the invention only comprise two single variable domains, which
are directed against different antigenic determinants, epitopes,
parts or domains or subunits of the same target. Again, such a
construct, and in particular the linkers or hinge region that link
the single variable domains to the constant domain(s), is
preferably such that both of the first single variable domains are
capable of binding to their intended or respective epitope,
antigenic determinant, part, domain or subunit, more preferably
essentially simultaneously.
[0099] The constant domains that are present in each of the
polypeptide chains that form a construct of the invention should be
such that they are capable of forming an Fc portion with the
constant domains that are present in the other polypeptide chain
that forms the construct of the invention. As mentioned above, for
this purpose, the constant domains that are present in both of the
polypeptide chains that form the construct of the invention will in
practice usually be essentially the same (i.e. be comprised of
essentially the same amino acid sequence). For example, the
constant domains may be C.sub.H2 and C.sub.H3 domains that are
capable of forming an IgG Fc portion (e.g. an IgG1, IgG2, IgG3 or
IgG4 Fc portion), C.sub..alpha.2 and C.sub..alpha.3 domains that
are capable of forming an IgA Fc portion, C.sub..delta.2 and
C.sub..delta.3 that are capable of forming an IgD Fc portion,
C.sub..mu.2, C.sub..mu.3 and C.sub..mu.4 domains that are capable
of forming an IgM Fc portion; or C.sub..epsilon.2, C.sub..epsilon.3
and C.sub..epsilon.4 domains that are capable of forming an IgE Fc
portion. The constant domains may also be such that they are
capable of forming a chimeric Fc portion. Preferably, the constant
domains are constant domains that are derived from human
antibodies, so that the Fc portion is the Fc portion of a human IgG
(e.g. an IgG1, IgG2, IgG3 or IgG4), IgA, IgM, IgD or IgE, or a
chimeric constant domain that is fully comprised of human constant
domains. By means of non-limiting example, nucleotide sequences
encoding the CH.sub.2 and CH.sub.3 domains of human IgG1 are given
in Table 1 (SEQ ID NOs: 12 and 13) below.
[0100] The constant domains may also be suitable parts, fragments,
analogs, variants or mutants of the aforementioned constant
domains, as long as they are capable of forming an Fc portion and
preferably are further such that they are still capable of
providing their desired effector functions. Again, the constant
domains that form the Fc portion are preferably essentially
comprised of human constant domains or of amino acid sequences that
are derived from human constant domains.
[0101] The specific constant domain(s) and/or Fc portion chosen
will depend upon the intended use and properties (such as effector
functions) of the final construct, and may be suitably chosen so as
to provide the desired properties (for example, binding and/or
activating complement, the ability to trigger ADCC, the ability to
trigger other immune responses, and/or other desired effector
functions) or to avoid such properties. Based on the disclosure
herein, a skilled person will be able to choose a suitable Fc
portion for a specific purpose or application. Usually, IgG-derived
Fc portions (such as IgG1, IgG2, IgG3 or IgG4-derived. Fc portions)
will be preferred. However, when the constructs of the invention
are directed against tumor cells or tumor antigens (such as HER-2),
they may also comprise an "IgE-derived Fc portion" (i.e. an Fc
portion that is derived from IgE) as described in the co-pending
International patent application of Ablynx N. V, entitled
"Constructs comprising single variable domains and an Fc portion
derived from IgE", which has the same filing date as the present
application.
[0102] In one specific, but non-limiting, aspect, the Fc portion
may also (be used to) confer upon the constructs the invention an
increased half-life in vivo. According to this aspect, the Fc
portion may still have some or all of its effector functions (or
have these effector functions, but at a reduced level still
suitable for the intended use), but when the Fc portion is solely
used to provide for increased half-life, also a suitable mutant,
variant part or fragment of an Fc portion may be used that has no
or essentially no effector functions. Half-life can generally be
defined as the time taken for the serum concentration of the
polypeptide to be reduce by 50%, in viva, for example due to
degradation of the ligand and/or clearance or sequestration of the
ligand by natural mechanisms. Methods for pharmacokinetic analysis
and determination of half-life are familiar to those skilled in the
art. Details may be found in Kenneth, A et al: Chemical Stability
of Pharmaceuticals: A Handbook for Pharmacists and in Peters et al,
Pharmacokinete analysis: A Practical Approach (1996). Reference is
also made to "Pharmacokinetics", M Gibaldi & D Perron,
published by Marcel Dekker, 2nd revised edition (1982). For
example, the constructs or polypeptides of the invention may have a
half-life in a mammal (such as a mouse, rat or monkey) and/or in
man that is at least 25%, preferably at least 50%, more preferably
at least 70%, such as about 80% or 90% or more, of a naturally
occurring IgE in said mammal or in man.
[0103] The invention also relates to a protein or polypeptide that
comprises or essentially consists of a construct of the
invention.
[0104] The invention further relates to a polypeptide chain that
forms part of a construct of the invention and/or that is capable
of forming (or can be used to form) a construct of the invention
(i.e. together with another such polypeptide chain), which.
polypeptide chain is as further described herein.
[0105] The invention further relates to nucleotide sequences or
nucleic acids that encode and/or that can be used to express a
construct of the invention and/or a polypeptide chain of the
invention. Such nucleotide sequences or nucleic acids (which are
also generally referred to herein as "nucleic acids of the
invention") may be as further described herein.
[0106] The invention further relates to methods for producing the
constructs and polypeptides of the invention; to compositions (and
in particular pharmaceutical compositions) that comprise one or
more constructs or polypeptide chains of the invention; and to uses
of the constructs or polypeptide chains of the invention or of
compositions comprising them. Such methods, compositions and uses
may be as further described herein.
[0107] Other aspects, embodiments, uses, applications and
advantages of the invention will be clear to the skilled person
from the further disclosure herein.
[0108] It should also be noted that, unless specifically defined
otherwise herein, all terms used in the present specification
either have the meaning given to them in the prior art cited herein
(and in particular given to them in WO 06/122786), or otherwise
have their usual meaning in the art, which will be clear to the
skilled person. Reference is for example made to the standard
handbooks, such as Sambrook et al, "Molecular Cloning: A Laboratory
Manual" (2nd. Ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press
(1989); F. Ausubel et al, eds., "Current protocols in molecular
biology", Green Publishing and Wiley Interscience, New York (1987);
Lewin, "Genes II", John Wiley & Sons, New York, N.Y., (1985);
Old et al., "Principles of Gene Manipulation: An Introduction to
Genetic Engineering", 2nd edition, University of California Press,
Berkeley, Calif. (1981); Roitt et al., "Immunology" (6th. Ed.),
Mosby/Elsevier, Edinburgh (2001); Roitt et al., Roitt's Essential
Immunology, 10.sup.th Ed. Blackwell Publishing, UK (2001); and
Janeway et al., "Immunobiology" (6th Ed.), Garland Science
Publishing/Churchill Livingstone, New York (2005), as well as to
the further prior art cited herein, such as WO 04/068820 and WO
02/056910. Also, all methods, steps, techniques and manipulations
that are not specifically described in detail in the present
specification can be performed in a manner known per se to the
skilled person, for which reference is again made to the prior art
cited herein (including WO 04/068820 and WO 02/056910) as well as
to the standard handbooks cited above.
[0109] In the context of the present invention, "modulating" or "to
modulate" generally means either reducing or inhibiting the
activity of, or alternatively increasing the activity of, a target
or antigen, as measured using a suitable in vitro, cellular or in
vivo assay. In particular, "modulating" or "to modulate" may mean
either reducing or inhibiting the activity of, or alternatively
increasing a (relevant or intended) biological activity of, a
target or antigen, as measured using a suitable in vitro, cellular
or in vivo assay (which will usually depend on the target or
antigen involved), by at least 1%, preferably at least 5%, such as
at least 10% or at least 25%, for example by at least 50%, at least
60%, at least 70%, at least 80%, or 90% or more, compared to
activity of the target or antigen in the same assay under the same
conditions but without the presence of the construct of the
invention.
[0110] As will be clear to the skilled person, "modulating" may
also involve effecting a change (which may either be an increase or
a decrease) in affinity, avidity, specificity and/or selectivity of
a target or antigen for one or more of its ligands, binding
partners, partners for association into a homomultimeric or
heteromultimeric form, or substrates; and/or effecting a change
(which may either be an increase or a decrease) in the sensitivity
of the target or antigen for one or more conditions in the medium
or surroundings in which the target or antigen is present (such as
pH, ion strength, the presence of co-factors, etc.), compared to
the same conditions but without the presence of the construct of
the invention. As will be clear to the skilled person, this may
again be determined in any suitable manner and/or using any
suitable assay known per se, depending on the target or antigen
involved.
[0111] "Modulating" may also mean effecting a change (i.e. an
activity as an agonist, as an antagonist or as a reverse agonist,
respectively, depending on the target or antigen and the desired
biological or physiological effect) with respect to one or more
biological or physiological mechanisms, effects, responses,
functions, pathways or activities in which the target or antigen
(or in which its substrate(s), ligand(s) or pathway(s) are
involved, such as its signalling pathway or metabolic pathway and
their associated biological or physiological effects) is involved.
Again, as will be clear to the skilled person, such an action as an
agonist or an antagonist may be determined in any suitable manner
and/or using any suitable (in vitro and usually cellular or in
vivo) assay known per se, depending on the target or antigen
involved. In particular, an action as an agonist or antagonist may
be such that an intended biological or physiological activity is
increased or decreased, respectively, by at least 1%, preferably at
least 5%, such as at least 10% or at least 25%, for example by at
least 50%, at least 60%, at least 70%, at least 80%, or 90% or
more, compared to the biological or physiological activity in the
same assay under the same conditions but without the presence of
the construct of the invention.
[0112] Modulating may for example also involve allosteric
modulation of the target or antigen; and/or reducing or inhibiting
the binding of the target or antigen to one of its substrates or
ligands and/or competing with a natural ligand, substrate for
binding to the target or antigen. Modulating may also involve
activating the target or antigen or the mechanism or pathway in
which it is involved. Modulating may for example also involve
effecting a change in respect of the folding or confirmation of the
target or antigen, or in respect of the ability of the target or
antigen to fold, to change its confirmation (for example, upon
binding of a ligand), to associate with other (sub)units, or to
disassociate. Modulating may for example also involve effecting a
change in the ability of the target or antigen to transport other
compounds or to serve as a channel for other compounds (such as
ions).
[0113] Modulating may be reversible or irreversible, but for
pharmaceutical and pharmacological purposes will usually be in a
reversible manner.
[0114] The single variable domains that are present in the
constructs of the invention may be any variable domain that forms a
single antigen binding unit. Generally, such single variable
domains will be amino acid sequences that essentially consist of 4
framework regions (FR1 to FR4 respectively) and 3 complementarity
determining regions (CDR1 to CDR3 respectively); or any suitable
fragment of such an amino acid sequence (which will then usually
contain at least some of the amino acid residues that form at least
one of the CDR's, as further described herein). Such single
variable domains and fragments are most preferably such that they
comprise an immunoglobulin fold or are capable for forming, under
suitable conditions, an immunoglobulin fold. As such, the single
variable domain may for example comprise a light chain variable
domain sequence (e.g. a V.sub.L-sequence) or a suitable fragment
thereof; or a heavy chain variable domain sequence (e.g. a
V.sub.H-sequence or V.sub.HH sequence) or a suitable fragment
thereof; as long as it is capable of forming a single antigen
binding unit (i.e. a functional antigen binding unit that
essentially consists of the single variable domain, such that the
single antigen binding domain does not need to interact with
another variable domain to form a functional antigen binding unit
or site, as is for example the case for the variable domains that
are present in for example conventional antibodies and ScFv
fragments that need to interact with another variable domain--e.g.
through a V.sub.H/V.sub.L interaction--to form a functional antigen
binding domain).
[0115] For example, the single variable domain may be a domain
antibody (or an amino acid sequence that is suitable for use as a
domain antibody), a single domain antibody (or an amino acid
sequence that is suitable for use as a single domain antibody), a
"dAb" (or an amino acid sequence that is suitable for use as a dAb)
or a Nanobody (as defined herein, and including but not limited to
a V.sub.HH sequence); other single variable domains, or any
suitable fragment of any one thereof. For a general description of
(single) domain antibodies, reference is also made to the prior art
cited above, as well as to EP 0 368 684. For the term "dAb's",
reference is for example made to Ward et al. (Nature 1989 Oct. 12;
341 (6242): 544-6), to Holt et al. (Trends Biotechnol., 2003,
21(11):484-490); as well as to for example WO 04/068820, WO
06/030220, WO 06/003388 and other published patent applications of
Domantis Ltd. It should also be noted that, although less preferred
in the context of the present invention because they are not of
mammalian origin, single domain antibodies or single variable
domains can be derived from certain species of shark (for example,
the so-called "IgNAR domains", see for example WO 05/18629).
[0116] In particular, the amino acid sequence of the invention may
be a Nanobody.TM. or a suitable fragment thereof. [Note:
Nanobody.RTM., Nanobodies.RTM. and Nanoclone.RTM. are trademarks of
Ablynx N. V] For a further description of V.sub.HH's and
Nanobodies, reference is made to the review article by Muyldermans
in Reviews in Molecular Biotechnology (74 (2001), 277-302); as well
as to the following patent applications, which are mentioned as
general background art: WO 94/04678, WO 95/04079 and WO 96/34103 of
the Vrije Universiteit Brussel; WO 94/25591, WO 99/37681, WO
00/40968, WO 00/43507, WO 00/65057, WO 01/40310, WO 01/44301, EP
1134231 and WO 02/48193 of Unilever; WO 97/49805, WO 01/21817, WO
03/035694, WO 03/054016 and WO 03/055527 of the Vlaams Instituut
voor Biotechnologie (VIB); WO 03/050531 of Algonomics N. V. and
Ablynx N. V.; WO 01/90190 by the National Research Council of
Canada; WO 03/025020 (=EP 1 433 793) by the Institute of
Antibodies; as well as WO 04/041867, WO 04/041862, WO 04/041865, WO
04/041863, WO 04/062551, WO 05/044858, WO 06/40153, WO 06/079372,
WO 06/122786, WO 06/122787 and WO 06/122825, by Ablynx N. V. and
the further published patent applications by Ablynx N. V. Reference
is also made to the further prior art mentioned in these
applications, and in particular to the list of references mentioned
on pages 41-43 of the International application WO 06/040153, which
list and references are incorporated herein by reference. As
described in these references, generally, Nanobodies (in particular
V.sub.I-114 sequences and partially humanized Nanobodies) can in
particular be characterized by the presence of one or more
"Hallmark residues" in one or more of the framework sequences.
[0117] The single variable domains used in the constructs of the
invention may be directed against (as defined in WO 06/122 825) any
suitable antigen. Examples of suitable antigens and of single
variable domains directed against those antigens will be clear to
the skilled person based on the disclosure herein, and for example
include the antigens and single variable domains mentioned in the
prior art cited herein as well as the antigens and "dAb's"
mentioned and described in the patent applications of Domantis Ltd.
or Domantis Inc.
[0118] The constructs of the invention may be prepared in any
suitable manner known per se. Usually, such methods will either
comprise joining two suitable polypeptide chains of the invention
so as to form a construct of the invention (in which these
polypeptide chains will usually be essentially identical in
sequence, although the invention in its broadest sense is not
limited thereto). For the purposes of this method, the polypeptide
chains of the invention may be prepared in any suitable manner,
usually by suitably expressing, in a suitable host or host
organism, a nucleic acid of the invention that encodes the desired
polypeptide chain.
[0119] Alternatively, the constructs of the invention may be
prepared by suitably co-expressing, in a suitable host or host
organism, (suitable nucleic acids of the invention that encode) two
suitable polypeptide chains of the invention (in which these
polypeptide chains will again usually be essentially identical in
sequence) so as to form a construct of the invention.
[0120] For the purposes of the above methods, the nucleic acids
encoding the polypeptide chains of the invention may be prepared in
any suitable manner, for example using PCR assembly using
overlapping primers, by suitably linking (naturally occurring,
synthetic or semi-synthetic) nucleotide sequences that encode the
various parts of the desired polypeptide chain, or by de novo
synthesis of the desired nucleic acid of the invention using an
automated apparatus for synthesizing nucleic acid sequences with a
predefined amino acid sequence. The particular codons used may also
be chosen and/or optimized for the host or host organism to be used
for the expression. Also, for the purposes of the invention, the
nucleic acids of the invention may be provided and/or used in the
form of a suitable genetic construct (such as a plasmid or
expression vector), that may for example comprise--in addition to
the nucleotide sequences that encodes the desired polypeptide
chain--one or more regulatory elements and/or other suitable
components of such constructs known per se. All this can be
performed using methods and techniques known per se, for which
reference is made to the prior art cited herein, such as WO
04/068820 and WO 02/056910. For example, nucleotide sequences
encoding the desired single variable domains can be suitably linked
to a nucleotide sequence that encodes the desired constant domains,
optionally via nucleotide sequences that encode suitable linkers or
hinge regions as described herein.
[0121] The further expression, production, purification and
isolation (including any steps for joining the two polypeptide
chains of the invention so as to form a construct of the invention,
or co-expressing two polypeptide chains of the invention so as to
form a construct of the invention) may be performed using
techniques, vectors, host cells or host organisms known per se, for
which reference is again made to for example WO 04/068820 and WO
02/056910.
[0122] In a further aspect, the invention relates to a host or host
cell that expresses or is capable of expressing a construct of the
invention or a polypeptide chain of the invention, or that contains
a nucleotide sequence or nucleic acid that encodes a construct of
the invention or a polypeptide chain of the invention. The
invention further relates to methods for producing a construct of
the invention or a polypeptide chain of the invention, comprising
maintaining or cultivating such a host or host cell under
conditions such that said host or host cell expresses or produces a
construct of the invention or a polypeptide chain of the invention,
and optionally comprising isolating the construct of the invention
or polypeptide chain of the invention so expressed or produced.
[0123] The invention further relates to compositions that comprise
at least one construct of the invention or a polypeptide chain of
the invention. Such a composition may in particular be a
pharmaceutical composition that comprises at least one construct of
the invention and one or more pharmaceutically acceptable carriers,
adjuvants or excipients. Reference is again made to for example WO
04/068820 and WO 02/056910, as well as to the further prior art
cited herein. Usually, such a pharmaceutical composition will be a
(usually liquid and aqueous) composition that is suitable for
injection or infusion, essentially similar to the formulations that
are used for injection or infusion of conventional monoclonal
antibodies, but containing one or more constructs of the invention
instead of a conventional 4-chain monoclonal antibody.
[0124] The constructs and compositions of the invention may be used
for any suitable purpose, mainly depending upon the antigen(s)
against which, the single variable domains that are present in the
construct are directed. For example, when the single variable
domains that are present in the construct are directed against a
pharmaceutically relevant target or antigen, the constructs and
compositions of the invention may be used in the prevention and/or
treatment of diseases and disorders that are associated with said
target or antigen, i.e. by suitably administering the constructs or
compositions to a subject that is at risk of and/or suffering from
said disease or disorder. Such diseases and disorders, and suitable
routes of administration and treatment regimens, will be clear to
the skilled person based on the disclosure herein. Generally, it is
envisaged that constructs of the invention can be made that are
analogous to conventional therapeutic monoclonal antibodies (i.e.
directed against the same target or antigen, but only containing
two polypeptide chains as described herein, in which the single
variable domains in each chain are directed against the relevant
target or antigen), and that such constructs (and pharmaceutical
compositions comprising the same) can be used for the prevention
and/or treatment of essentially the same diseases and disorders as
these conventional monoclonals, using essentially similar routes of
administration and treatment regimens, which can easily be
determined by the treating physician.
[0125] Thus, in another aspect, the invention relates to (the use
of) a construct of the invention that is directed against a desired
or intended (therapeutically relevant) target or antigen (or of a
pharmaceutical composition comprising the same) for the prevention
or treatment of a disease or disorder associated with said target
or antigen.
[0126] The invention further relates to the use of a construct of
the invention that is directed against a desired or intended
(therapeutically relevant) target or antigen in the preparation of
a pharmaceutical composition for the prevention or treatment of a
disease or disorder associated with said target or antigen.
[0127] The invention also relates to a method for preventing or
treating a disease or disorder that is associated with a target or
antigen, which method comprises administering, to a subject in need
of such prevention or treatment, of a therapeutically active amount
of a construct of the invention that is directed against said
target or antigen (or of a pharmaceutical composition comprising
the same).
[0128] As mentioned herein, in one specifically preferred, but
non-limiting aspect, the construct of the invention is directed
against HER-2. Such constructs of the invention are particularly
suited for the prevention and/or treatment of various forms of
cancer and tumors (including solid tumors), e.g. by slowing,
stopping or reversing the growth of a tumor and/or by slowing,
stopping or reversing the spread of metastases caused by the tumor;
and it is envisaged that such constructs of the invention may have
improved efficacy and/or other improved properties compared to
conventional 4-chain monoclonal antibodies against HER-2, such as
for example Herceptin.RTM. or Omnitarg.RTM.. The efficacy of the
constructs of the invention that are directed against HER-2 may be
determined using suitable cellular assays (for example using a
suitable tumor cell line) or animal models known per se, which may
be suitably chosen by the skilled person.
[0129] Again, for use of the anti-HER-2 constructs of the invention
in the prevention and/or treatment of cancer, suitable constructs
of the invention, pharmaceutical compositions, routes of
administration and treatment regimens will be clear to the skilled
person based on the disclosure herein, and may for example also
include suitable combination treatments with other cytostatic
agents and/or with surgery and/or radiation treatment.
[0130] Thus, in another aspect, the invention relates to (the use
of) a construct of the invention that is directed against HER-2 (or
of a pharmaceutical composition comprising the same) for the
prevention or treatment of cancer (and in particular, for the
prevention or treatment of tumors that (over)express HER-2).
[0131] The invention further relates to the use of a construct of
the invention that is directed against HER-2 in the preparation of
a pharmaceutical composition for the prevention or treatment of
cancer (and in particular, of tumors that express said
tumor-associated target or antigen).
[0132] The invention also relates to a method for preventing or
treating a cancer, which method comprises administering, to a
subject in need of such prevention or treatment, of a
therapeutically active amount of a construct of the invention that
is directed against HER-2 or of a pharmaceutical composition
comprising the same.
[0133] As mentioned herein, in another specifically preferred, but
non-limiting aspect, the construct of the invention is directed
against a heterodimeric cytokine, such as against IL-12, IL-23,
IL-27 or IL-35. Such constructs of the invention are particularly
suited for the prevention and/or treatment of a disease or disorder
associated with said heterodimeric cytokine (i.e. with IL-12,
IL-23, IL-27 and/or IL-35, respectively). For such diseases and
disorders, reference is again made to the co-pending International
patent application of Ablynx N. V. entitled "Amino acid sequences
directed against heterodimeric cytokines and/or their receptors and
polypeptides comprising the same" of Ablynx N. V., which has the
same filing date as the present application. Such constructs may in
particular be directed against IL-23, as further described
herein.
[0134] Thus, in another aspect, the invention relates to (the use
of) a construct of the invention that is directed against a
heterodimeric cytokine (or of a pharmaceutical composition
comprising the same), such as against IL-12, IL-23, IL-27 or IL-35,
for the prevention or treatment of a disease or disorder associated
with said heterodimeric cytokine (i.e. with IL-12, IL-23, IL-27
and/or IL-35, respectively).
[0135] The invention further relates to the use of a construct of
the invention that is directed against a heterodimeric cytokine,
such as against IL-12, IL-23, IL-27 or IL-35, in the preparation of
a pharmaceutical composition for the prevention or treatment of a
disease or disorder associated with said heterodimeric cytokine
(i.e. with IL-12, IL-23, IL-27 and/or IL-35, respectively).
[0136] The invention also relates to a method for preventing or
treating a disease or disorder that is associated with a
heterodimeric cytokine, such as with IL-12, IL-23, IL-27 or IL-35,
which method comprises administering, to a subject in need of such
prevention or treatment, of a therapeutically active amount of a
construct of the invention that is directed against a heterodimeric
cytokine, such as against IL-12, IL-23, IL-27 or IL-35 (or of a
pharmaceutical composition comprising the same).
[0137] SEQ ID NO's 1 to 11, FIGS. 5 to 9 and Table 1 below give
some non-limiting examples of amino acid sequences and nucleic acid
sequences of polypeptide chains of the invention that can be used
to form constructs of the invention: [0138] SEQ ID NO:1 and FIG. 5A
give an example of an amino acid sequence of a polypeptide chain of
the invention comprising two different Nanobodies against HER-2
(i.e. 47D5 and 2D3, which together form a biparatopic Nanobody
construct), that are linked via a hinge region (encoded by the
nucleotide sequence of SEQ ID NO:14) to the CH.sub.2 and CH.sub.3
domains of human IgG1 (encoded by the nucleotide sequence of SEQ ID
NO:12 and SEQ ID NO:13, respectively). In this construct, 47D5 and
2D3 are linked to each other via 35 a.a. Gly/Ser linker, which
should allow both Nanobodies to bind to HER-2 (i.e. essentially
simultaneously). The corresponding nucleotide sequence is given in
SEQ ID NO:2 and FIG. 5B. [0139] SEQ ID NO:3 and FIG. 6A give
another example of an amino acid sequence of a polypeptide chain of
the invention comprising two different Nanobodies against HER-2
(i.e. 47D5 and 2D3, which together form a biparatopic Nanobody
construct), that are linked via a hinge region (encoded by the
nucleotide sequence of SEQ ID NO:14) to the CH.sub.2 and CH.sub.3
domains of human IgG1 (encoded by the nucleotide sequence of SEQ ID
NO:12 and SEQ ID NO:13, respectively). In this construct, 47D5 and
2D3 are again linked to each other via 35 a.a. Gly/Ser linker,
which should allow both Nanobodies to bind to HER-2 (i.e.
essentially simultaneously); however, compared to the construct of
SEQ ID NO:1/FIG. 5A, the order of the 2 anti-HER-2 Nanobodies 47D5
and 2D3 is reversed. The corresponding nucleotide sequence is given
in SEQ ID NO:4 and FIG. 6B. [0140] SEQ ID NO:5 and FIG. 7A give an
example of an amino acid sequence of a polypeptide chain of the
invention comprising two different Nanobodies against HER-2 (i.e.
47D5 and 2D3, which together form a biparatopic Nanobody
construct), that are linked via a glycine-serine linker and the
native C.sub..epsilon.1-C.sub..epsilon.2 linking sequence to the
C.sub..epsilon.2, C.sub..epsilon.3 and C.sub..epsilon.4 domains of
human IgE. In this construct, 47D5 and 2D3 are linked to each other
via 35 a.a. Gly/Ser linker, which should allow both Nanobodies to
bind to HER-2 (i.e. essentially simultaneously). The corresponding
nucleotide sequence is given in SEQ ID NO:6 and FIG. 7B. [0141] SEQ
ID NO:7 and FIG. 8A give another example of an amino acid sequence
of a polypeptide chain of the invention comprising two different
Nanobodies against HER-2 (i.e. 47D5 and 2D3, which together form a
biparatopic Nanobody construct), that are linked via a
glycine-serine linker and the native
C.sub..epsilon.1-C.sub..epsilon.2 linking sequence to the
C.sub..epsilon.2, C.sub..epsilon.3 and C.sub..epsilon.4 domains of
human IgE. In this construct, 47D5 and 2D3 are again linked to each
other via 35 a.a. Gly/Ser linker, which should allow both
Nanobodies to bind to HER-2 (i.e. essentially simultaneously);
however, compared to the construct of SEQ ID NO:5/FIG. 7A, the
order of the 2 anti-HER-2 Nanobodies 47D5 and 2D3 is reversed. The
corresponding nucleotide sequence is given in SEQ ID NO:8 and FIG.
8B.
[0142] FIGS. 9A to 9C give examples of constructs of the invention
that are directed against IL-23. The construct of FIG. 9A (SEQ ID
NO:9) comprises one Nanobody (121A2 p19+) that can bind to the p19
subunit of IL-23 and that can modulate (and in particular, reduce)
binding of IL-23 to its receptor, and one Nanobody (81G2 p19-) that
can bind to the p19 subunit of IL-23 but that does not modulate
binding of IL-23 to its receptor. The construct of FIG. 9B (SEQ ID
NO:10) comprises one Nanobody (121A2 p19+) that can bind to the p19
subunit of IL-23 and that can modulate (and in particular, reduce)
binding of IL-23 to its receptor, and one Nanobody (81E10 p40+)
that can bind to the p40 subunit of IL-23 and that can modulate
binding of IL-23 to its receptor. Because IL-12 shares the p40
subunit with IL-23, it is expected that this construct can also
bind to IL-12 (but with less avidity) and that this construct shows
selectivity for IL-23 compared to IL-12. The construct of FIG. 9C
(SEQ ID NO:11) comprises one Nanobody (81E10 p40+) that can bind to
the p40 subunit of IL-23 and that can modulate binding of IL-23 to
its receptor, and one Nanobody (80D10) that can bind to the p40
subunit of IL-23 but that does not modulate binding of IL-23 to its
receptor. Because IL-12 shares the p40 subunit with IL-23, it is
expected that this construct can also bind to IL-12, also with
improved avidity.
TABLE-US-00001 TABLE 1 Non-limiting examples of amino acid
sequences and nucleic acid sequences of polypeptide chains of the
invention. 47D5-35GS-2D3-hinge-CH2-CH3; SEQ ID NO: 1
kvqlvesggglvqpggslrlscaasgsifgfndmawyrqapgkqrelva
lisrvgvtssadsvkgrftisrvnakdtvylqmnslkpedtavyycymd
qrldgstlaywgqgtqvtvssggggsggggsggggsggggsggggsggg
gsggggsevqlvesggslvqpggslrlscaasgftfddyamswvrqvpg
kglewvssinwsgthtdyadsvkgrftisrnnanntlylqmnslksedt
avyycaknwrdagttwfeksgsagqgtqvtvssEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK 47D5-35GS-2B3-hinge-CH2-CH3; SEQ ID NO: 2
aaggtgcagctggtggagtctgggggaggcttggtgcagcctggggggt
ctctgagactctcctgtgcagcctctggaagcatcttcggtttcaatga
catggcctggtaccgccaggctccagggaagcagcgcgagttggtcgca
ctaattagtagggttggtgtcacaagttctgcagactccgtgaagggcc
gattcaccatctccagagtcaacgccaaggacacggtgtatctgcaaat
gaacagcctgaaacctgaggatacggccgtctattattgttatatggat
cagcgactcgacggtagtactttagcgtactggggccaggggacccagg
tcaccgtatcgagtgggggcgggggaagtggcggaggtgggtccggtgg
cggaggcagcggtggaggaggtagtggcggtggcggtagtggcggtggc
ggcagtggaggcggaggatccgaagtgcagttagtcgagtcagggggta
gcttggtgcagccggggggtagcctgcgcctgagctgcgccgcgagcgg
cttcaccttcgacgattatgcgatgtcatgggtcagacaggtccctggt
aaagggcttgaatgggtttcctcaataaactggagcggcacccatacgg
attatgcggatagcgtgaaaggacgttttaccattagccgcaataacgc
taataacactctgtacctacaaatgaactcgctcaaatctgaagatact
gctgtctactattgtgccaagaattggcgtgacgcagggaccacatggt
ttgagaaatccggtagcgcgggccaaggcactcaggtgacagtgagcag
cAgcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagCac
ctgaactcctggggggaccgtcagtcttcctcttccccccaaaacccaa
ggacaccctcatgatctcccggacccctgaggtcacatgcgtggtggtg
gacgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacg
gcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaa
cagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactgg
ctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccag
cccccatcgagaaaaccatctccaaagccaaagGgcagccccgagaacc
acaggtgtacaccctgcccccatcccgggatgagctgaccaagaaccag
gtcagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccg
tggagtgggagagcaatgggcagccggagaacaactacaagaccacgcc
tcccgtgctggactccgacggctccttcttcctctacagcaagctcacc
gtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtga
tgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtc tccgggtaaatga
2D3-35GS-47D5-hinge-CH2-CH3; SEQ ID NO: 3
EVQLVESGGSLVQPGGSLRLSCAASGFTFDDYAMSWVRQVPGKGLEWVS
SINWSGTHTDYADSVKGRFTISRNNANNTLYLQMNSLKSEDTAVYYCAK
NWRDAGTTWFEKSGSAGQGTQVTVSSGGGGSGGGGSGGGGSGGGGSGGG
GSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGSIFGFNDMAWY
RQAPGKQRELVALISRVGVTSSADSVKGRFTISRVNAKDTVYLQMNSLK
PEDTAVYYCYMDQRLDGSTLAYWGQGTQVTVSSEPKSCDKTHTCPPCPA
PELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD
GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALP
APIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIA
VEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK 2D3-35GS-47D5-hinge-CH2-C113; SEQ ID NO: 4
gaggtgcagaggtggagtctgggggctccttggtgcagcctggggggtc
tctgagactctcctgtgcagcctaggcttcacttttgatgattatgcca
tgagctgggtccgacaggttccagggaaggggttggagtgggtttcatc
tattaattggtctggtactcacacagactatgcagactccgtgaagggc
cgattcaccatctccagaaacaacgccaataacacgctgtatctacaaa
tgaacagtctgaaatctgaggacacggccgtgtattactgtgcaaaaaa
ctggagagacgcaggtactacctggttcgaaaagtccggctccgcgggc
caggggacccaggtcaccgtatcgagtgggggcgggggaagtggcggag
gtgggtccggtggcggaggcagcggtggaggaggtagtggcggtggcgg
tagtggcggtggcggcagtggaggcggaggatccgaggtgcagctggtg
gagtctgggggaggcttggtgcagcctggggggtctctgagactctcct
gtgcagcctctggaagcatcttcggtttcaatgacatggcctggtaccg
ccaggctccagggaagcagcgcgagttggtcgcactaattagtagggtt
ggtgtcacaagttctgcagactccgtgaagggccgattcaccatctcca
gagtcaacgccaaggacacggtgtatctgcaaatgaacagcctgaaacc
tgaggatacggccgtctattattgttatatggatcagcgactcgacggt
agtactttagcgtactggggccaggggacccaggtcaccgtctcctcaA
gcccaaatcttgtgacaaaactcacacatgcccaccgtgcccagCacct
gaactcctggggggaccgtcagtcttcctcttccccccaaaacccaagg
acaccctcatgatctcccggacccctgaggtcacatgcgtggtggtgga
cgtgagccacgaagaccctgaggtcaagttcaactggtacgtggacggc
gtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaaca
gcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggct
gaatggcaaggagtacaagtgcaaggtctccaacaaagccacccagccc
ccatcgagaaaaccatctecaaagccaaagGgcagccccgagaaccaca
ggtgtacaccctgcccccatcccgggatgagctgaccaagaaccaggtc
agcctgacctgcaggtcaaaggcttctatcccagcgacatcgccgtgga
gtgggagagcaatgggcagccggagaacaactacaagaccacgcctccc
gtgctggactccgacggctccttctcctctacagcaagctcaccgtgga
caagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcat
gaggctctgcacaaccactacacgcagaagagcctctccctgtctccgg gtaaatga Her2
47D5-G/S-2D3-G/S-C2-3-4 IgE; SEQ ID NO: 5
KVQLVESGGGLVQPGGSLRLSCAASGSIFGFNDMAWYRQAPGKQRELVA
LISRVGVTSSADSVKGRFTISRVNAKDTVYLQMNSLKPEDTAVYYCYMD
QRLDGSTLAYWGQGTQVTVSSGGGGSGGGGSGGGGSGGGGSGGGGSGGG
GSGGGGSEVQLVESGGSLVQPGGSLRLSCAASGFTFDDYAMSWVRQVPG
KGLEWVSSINWSGTHTDYADSVKGRFTISRNNANNTLYLQMNSLKSEDT
AVYYCAKNWRDAGTTWFEKSGSAGQGTQVTVSSGGGSGGGSGGGSVDNK
TFSVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITW
LEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQ
GHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPS
KGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGET
YQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLAC
LIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTR
AEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK Her2 47D5-G/S-2D3-G/S-C2-3-4
IgE; SEQ ID NO: 6 aaggtgcagctggtggagtctgggggaggcttggtgcagcctggggggt
ctctgagactctcctgtgcagcctctggaagcatcttcggtttcaatga
catggcctggtaccgccaggctccagggaagcagcgcgagttggtcgca
ctaattagtagggttggtgtcacaagttctgcagactccgtgaagggcc
gattcaccatctccagagtcaacgccaaggacacggtgtatctgcaaat
gaacagcctgaaacctgaggatacggccgtctattattgttatatggat
cagcgactcgacggtagtactttagcgtactggggccaggggacccagg
tcaccgtatcgagtgggggcgggggaagtggcggaggtgggtccggtgg
cggaggcagcggtggaggaggtagtggcggtggcggtagtggcggtggc
ggcagtggaggcggaggatccgaagtgcagttagtcgagtcagggggta
gcttggtgcagccggggggtagcctgcgcctgagctgcgccgcgagcgg
cttcaccttcgacgattatgcgatgtcatgggtcagacaggtccctggt
aaagggcttgaatgggtttcctcaataaactggagcggcacccatacgg
attatgcggatagcgtgaaaggacgttttaccattagccgcaataacgc
taataacactctgtacctacaaatgaactcgctcaaatctgaagatact
gctgtctactattgtgccaagaattggcgtgacgcagggaccacatggt
ttgagaaatccggtagcgcgggccaaggcactcaggtgacagtgagcag
cGGCGGCGGCAGCGGCGGCGGCAGCGGCGGCGGCAGCgtcgacaacaaa
accttcagcgtctgctccagggacttcaccccgcccaccgtgaagatct
tacagtcgtcctgcgacggcggcgggcacttccccccgaccatccagct
cctgtgcctcgtctctgggtacaccccagggactatcaacatcacctgg
ctggaggacgggcaggtcatggacgtggacttgtccaccgcctctacca
cgcaggagggtgagctggcctccacacaaagcgagctcaccctcagcca
gaagcactggctgtcagaccgcacctacacctgccaggtcacctatcaa
ggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccga
gaggggtgagcgcctacctaagccggcccagcccgttcgacctgttcat
ccgcaagtcgcccacgatcacctgtctggtggtggacctggcacccagc
aaggggaccgtgaacctgacctggtcccgggccagtgggaagcctgtga
accactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgt
cacgtccaccctgccggtgggcacccgagactggatcgagggggagacc
taccagtgcagggtgacccacccccacctgcccagggccctcatgcggt
ccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtt
tgcgacgccggagtggccggggagccgggacaagcgcaccctcgcctgc
ctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcaca
acgaggtgcagctcccggacgcccggcacagcacgacgcagccccgcaa
gaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagg
gccgaatgggagcagaaagatgagttcatctgccgtgcagtccatgagg
cagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccgg taaatga Her2
2D3-G/S-47D5-G/S-C2-3-4 IgE; SEQ ID NO: 7
EVQLVESGGSLVQPGGSLRLSCAASGETFDDYAMSWVRQVPGKGLEWVS
SINWSGTHTDYADSVKGRFTISRNNANNTLYLQMNSLKSEDTAVYYCAK
NWRDAGTTWFEKSGSAGQGTQVTVSSGGGGSGGGGSGGGGSGGGGSGGG
GSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGSIFGFNDMAWY
RQAPGKQRELVALISRVGVTSSADSVKGRFTISRVNAKDTVYLQMNSLK
PEDTAVYYCYMDQRLDGSTLAYWGQGTQVTVSSGGGSGGGSGGGSVDNK
TFSVCSRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITW
LEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQ
GHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPS
KGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGET
YQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLAC
LIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTR
AEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK Her2 2D3-G/S-47D5-G/S-C2-3-4
IgE; SEQ ID NO: 8 gaggtgcagctggtggagtctgggggctccttggtgcagcctggggggt
ctctgagactctcctgtgcagcctctggcttcacttttgatgattatgc
catgagctgggtccgacaggttccagggaaggggttggagtgggtttca
tctattaattggtctggtactcacacagactatgcagactccgtgaagg
gccgattcaccatctccagaaacaacgccaataacacgctgtatctaca
aatgaacagtctgaaatctgaggacacggccgtgtattactgtgcaaaa
aactggagagacgcaggtactacctggttcgaaaagtccggctccgcgg
gccaggggacccaggtcaccgtatcgagtgggggcgggggaagtggcgg
aggtgggtccggtggcggaggcagcggtggaggaggtagtggcggtggc
ggtagtggcggtggcggcagtggaggcggaggatccgaggtgcagctgg
tggagtctgggggaggcttggtgcagcctggggggtctctgagactctc
ctgtgcagcctctggaagcatcttcggtttcaatgacatggcctggtac
cgccaggctccagggaagcagcgcgagttggtcgcactaattagtaggg
ttggtgtcacaagttctgcagactccgtgaagggccgattcaccatctc
cagagtcaacgccaaggacacggtgtatctgcaaatgaacagcctgaaa
cctgaggatacggccgtctattattgttatatggatcagcgactcgacg
gtagtactttagcgtactggggccaggggacccaggtcaccgtctcctc
aGGCGGCGGCAGCGGCGGCGGCAGCGGCGGCGGCAGCgtcgacaacaaa
accttcagcgtctgctccagggacttcaccccgcccaccgtgaagatct
tacagtcgtcctgcgacggcggcgggcacttccccccgaccatccagct
cctgtgcctcgtctctgggtacaccccagggactatcaacatcacctgg
ctggaggacgggcaggtcatggacgtggacttgtccaccgcctctacca
cgcaggagggtgagctggcctccacacaaagcgagctcaccctcagcca
gaagcactggctgtcagaccgcacctacacctgccaggtcacctatcaa
ggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccga
gaggggtgagcgcctacctaagccggcccagcccgttcgacctgttcat
ccgcaagtcgcccacgatcacctgtctggLggtggacctggcacccagc
aaggggaccgtgaacctgacctggtcccgggccagtgggaagcctgtga
accactccaccagaaaggaggagaagcagcgcaatggcacgttaaccgt
cacgtccaccctgccggtgggcacccgagactggatcgagggggagacc
taccagtgcagggtgacccacccccacctgcccagggccctcatgcggt
ccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgtt
tgcgacgccggagtggccggggagccgggacaagcgcaccctcgcctgc
ctgatccagaacttcatgcctgaggacatctcggtgcagtggctgcaca
acgaggtgcagctcccggacgcccggcacagcacgacgcagccccgcaa
gaccaagggctccggcttcttcgtcttcagccgcctggaggtgaccagg
gccgaatgggagcagaaagatgagttcatctgccgtgcagtccatgagg
cagcgagcccctcacagaccgtccagcgagcggtgtctgtaaatcccgg taaatga 121A2
(p19+)-35GS-81G2 (p19-)-Hinge-CH2-CH3; SEQ ID NO: 9
EVQLVESGGGLVQAGGSLRLSCAASGSIFNFNYMGWFRQAPGKEREFVA
AIRWSGSSTYYADSVKGRFTISRDDAKNTVALQMNSLKPEDTAIYYCAL
RKGIPYSTSDRVIKGVNDYDYWGQGTQVTVSSGGGGSGGGGSGGGGSGG
GGSGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCIASGLPFST
KSMGWFRQAPGKEREFVARISPGGTSRYYGDFVKGRFAISRDNAKNTTW
LQMNSLKAEDTAVYYCASGERSTYIGSNYYRTNEYDYWGTGTQVTVSSE
PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWL
NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQV
SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTV
DKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 121A2 (p19+)-35GS-81E10
(p40+)-Hinge-CH2-CH3; SEQ ID NO: 10
EVQLVESGGGLVQAGGSLRLSCAASGSIFNFNYMGWFRQAPGKEREFVA
AIRWSGSSTYYADSVKGRFTISRDDAKNTVALQMNSLKPEDTAIYYCAL
RKGIPYSTSDRVIKGVNDYDYWGQGTQVTVSSGGGGSGGGGSGGGGSGG
GGSGGGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLRLSCVASGRTFNT
YGMGWFRQAPGKEREFVAANNWSGGATSYADSVKGRFTISRDNAKNTVF
LQMNTLKPEDTAVYYCAAADRGGGWLVVRENDYDYWGQGTQVTVSSEPK
SCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS
HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNG
KEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 81E10 (p40+)-35GS-80D10
(p40-)Hinge-CH2-CH3; SEQ ID NO: 11
EVQLVESGGGLVQAGGSLRLSCVASGRTFNTYGMGWFRQAPGKEREFVA
ANNWSGGATSYADSVKGRFTISRDNAKNTVFLQMNTLKPEDTAVYYCAA
ADRGGGWLVVRENDYDYWGQGTQVTVSSGGGGSGGGGSGGGGSGGGGSG
GGGSGGGGSGGGGSEVQLVESGGGLVQAGGSLRLSCAASGRTFEGNPMG
WFRQASGKKREFVASIDWSGGITSYADSVKGRFTISRDNAKNTVYLQMN
SLKPEDTAVYYCAASARFGSGSYYDLMYDYWGQGTQVTVSSEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPE
VKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC
KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK
GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK Human CH2; SEQ ID NO: 12
Cacctgaactcctggggggaccgtcagtcttcctcttccccccaaaacc
caaggacaccctcatgatctcccggacccctgaggtcacatgcgtggtg
gtggacgtgagccacgaagaccctgaggtcaagttcaactggtacgtgg
acggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagta
caacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggac
tggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcc
cagcccccatcgagaaaaccatctccaaagccaaag Human CH3; SEQ ID NO: 13
Ggcagccccgagaaccacaggtgtacaccctgcccccatcccgggatga
gctgaccaagaaccaggtcagcctgacctgcctggtcaaaggcttctat
cccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca
actacaagaccacgcctcccgtgaggactccgacggctcatatcctcta
cagcaagetcaccgtggacaagagcaggtggcagcaggggaacgtcttc
tcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaaga
gcctctccctgtctccgggtaaatga Hinge; SEQ ID NO: 14
Agcccaaatcttgtgacaaaactcacacatgcccaccgtgcccag
Sequence CWU 1
1
141510PRTArtificial sequenceNanobody construct 1Lys Val Gln Leu Val
Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Ser Ile Phe Gly Phe Asn 20 25 30Asp Met Ala
Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val 35 40 45Ala Leu
Ile Ser Arg Val Gly Val Thr Ser Ser Ala Asp Ser Val Lys 50 55 60Gly
Arg Phe Thr Ile Ser Arg Val Asn Ala Lys Asp Thr Val Tyr Leu65 70 75
80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr
85 90 95Met Asp Gln Arg Leu Asp Gly Ser Thr Leu Ala Tyr Trp Gly Gln
Gly 100 105 110Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Glu Val Gln Leu Val Glu145 150 155 160Ser Gly Gly Ser Leu Val
Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys 165 170 175Ala Ala Ser Gly
Phe Thr Phe Asp Asp Tyr Ala Met Ser Trp Val Arg 180 185 190Gln Val
Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asn Trp Ser 195 200
205Gly Thr His Thr Asp Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile
210 215 220Ser Arg Asn Asn Ala Asn Asn Thr Leu Tyr Leu Gln Met Asn
Ser Leu225 230 235 240Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala
Lys Asn Trp Arg Asp 245 250 255Ala Gly Thr Thr Trp Phe Glu Lys Ser
Gly Ser Ala Gly Gln Gly Thr 260 265 270Gln Val Thr Val Ser Ser Glu
Pro Lys Ser Cys Asp Lys Thr His Thr 275 280 285Cys Pro Pro Cys Pro
Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe 290 295 300Leu Phe Pro
Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro305 310 315
320Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val
325 330 335Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
Lys Thr 340 345 350Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
Val Val Ser Val 355 360 365Leu Thr Val Leu His Gln Asp Trp Leu Asn
Gly Lys Glu Tyr Lys Cys 370 375 380Lys Val Ser Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser385 390 395 400Lys Ala Lys Gly Gln
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro 405 410 415Ser Arg Asp
Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val 420 425 430Lys
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly 435 440
445Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp
450 455 460Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp465 470 475 480Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
His Glu Ala Leu His 485 490 495Asn His Tyr Thr Gln Lys Ser Leu Ser
Leu Ser Pro Gly Lys 500 505 51021532DNAArtificial sequenceNanobody
construct 2aaggtgcagc tggtggagtc tgggggaggc ttggtgcagc ctggggggtc
tctgagactc 60tcctgtgcag cctctggaag catcttcggt ttcaatgaca tggcctggta
ccgccaggct 120ccagggaagc agcgcgagtt ggtcgcacta attagtaggg
ttggtgtcac aagttctgca 180gactccgtga agggccgatt caccatctcc
agagtcaacg ccaaggacac ggtgtatctg 240caaatgaaca gcctgaaacc
tgaggatacg gccgtctatt attgttatat ggatcagcga 300ctcgacggta
gtactttagc gtactggggc caggggaccc aggtcaccgt atcgagtggg
360ggcgggggaa gtggcggagg tgggtccggt ggcggaggca gcggtggagg
aggtagtggc 420ggtggcggta gtggcggtgg cggcagtgga ggcggaggat
ccgaagtgca gttagtcgag 480tcagggggta gcttggtgca gccggggggt
agcctgcgcc tgagctgcgc cgcgagcggc 540ttcaccttcg acgattatgc
gatgtcatgg gtcagacagg tccctggtaa agggcttgaa 600tgggtttcct
caataaactg gagcggcacc catacggatt atgcggatag cgtgaaagga
660cgttttacca ttagccgcaa taacgctaat aacactctgt acctacaaat
gaactcgctc 720aaatctgaag atactgctgt ctactattgt gccaagaatt
ggcgtgacgc agggaccaca 780tggtttgaga aatccggtag cgcgggccaa
ggcactcagg tgacagtgag cagcagccca 840aatcttgtga caaaactcac
acatgcccac cgtgcccagc acctgaactc ctggggggac 900cgtcagtctt
cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg
960aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag
ttcaactggt 1020acgtggacgg cgtggaggtg cataatgcca agacaaagcc
gcgggaggag cagtacaaca 1080gcacgtaccg tgtggtcagc gtcctcaccg
tcctgcacca ggactggctg aatggcaagg 1140agtacaagtg caaggtctcc
aacaaagccc tcccagcccc catcgagaaa accatctcca 1200aagccaaagg
gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggatgagc
1260tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc
agcgacatcg 1320ccgtggagtg ggagagcaat gggcagccgg agaacaacta
caagaccacg cctcccgtgc 1380tggactccga cggctccttc ttcctctaca
gcaagctcac cgtggacaag agcaggtggc 1440agcaggggaa cgtcttctca
tgctccgtga tgcatgaggc tctgcacaac cactacacgc 1500agaagagcct
ctccctgtct ccgggtaaat ga 15323510PRTArtificial sequenceNanobody
construct 3Glu Val Gln Leu Val Glu Ser Gly Gly Ser Leu Val Gln Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Asp Asp Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Val Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ser Ser Ile Asn Trp Ser Gly Thr His Thr Asp
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asn Asn
Ala Asn Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Lys Ser
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Lys Asn Trp Arg Asp Ala
Gly Thr Thr Trp Phe Glu Lys Ser Gly 100 105 110Ser Ala Gly Gln Gly
Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly
Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu145 150
155 160Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
Ser 165 170 175Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Gly
Phe Asn Asp 180 185 190Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln
Arg Glu Leu Val Ala 195 200 205Leu Ile Ser Arg Val Gly Val Thr Ser
Ser Ala Asp Ser Val Lys Gly 210 215 220Arg Phe Thr Ile Ser Arg Val
Asn Ala Lys Asp Thr Val Tyr Leu Gln225 230 235 240Met Asn Ser Leu
Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr Met 245 250 255Asp Gln
Arg Leu Asp Gly Ser Thr Leu Ala Tyr Trp Gly Gln Gly Thr 260 265
270Gln Val Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr
275 280 285Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser
Val Phe 290 295 300Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
Ser Arg Thr Pro305 310 315 320Glu Val Thr Cys Val Val Val Asp Val
Ser His Glu Asp Pro Glu Val 325 330 335Lys Phe Asn Trp Tyr Val Asp
Gly Val Glu Val His Asn Ala Lys Thr 340 345 350Lys Pro Arg Glu Glu
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val 355 360 365Leu Thr Val
Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys 370 375 380Lys
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser385 390
395 400Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
Pro 405 410 415Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr
Cys Leu Val 420 425 430Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
Trp Glu Ser Asn Gly 435 440 445Gln Pro Glu Asn Asn Tyr Lys Thr Thr
Pro Pro Val Leu Asp Ser Asp 450 455 460Gly Ser Phe Phe Leu Tyr Ser
Lys Leu Thr Val Asp Lys Ser Arg Trp465 470 475 480Gln Gln Gly Asn
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His 485 490 495Asn His
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 500 505
51041532DNAArtificial sequenceNanobody construct 4gaggtgcagc
tggtggagtc tgggggctcc ttggtgcagc ctggggggtc tctgagactc 60tcctgtgcag
cctctggctt cacttttgat gattatgcca tgagctgggt ccgacaggtt
120ccagggaagg ggttggagtg ggtttcatct attaattggt ctggtactca
cacagactat 180gcagactccg tgaagggccg attcaccatc tccagaaaca
acgccaataa cacgctgtat 240ctacaaatga acagtctgaa atctgaggac
acggccgtgt attactgtgc aaaaaactgg 300agagacgcag gtactacctg
gttcgaaaag tccggctccg cgggccaggg gacccaggtc 360accgtatcga
gtgggggcgg gggaagtggc ggaggtgggt ccggtggcgg aggcagcggt
420ggaggaggta gtggcggtgg cggtagtggc ggtggcggca gtggaggcgg
aggatccgag 480gtgcagctgg tggagtctgg gggaggcttg gtgcagcctg
gggggtctct gagactctcc 540tgtgcagcct ctggaagcat cttcggtttc
aatgacatgg cctggtaccg ccaggctcca 600gggaagcagc gcgagttggt
cgcactaatt agtagggttg gtgtcacaag ttctgcagac 660tccgtgaagg
gccgattcac catctccaga gtcaacgcca aggacacggt gtatctgcaa
720atgaacagcc tgaaacctga ggatacggcc gtctattatt gttatatgga
tcagcgactc 780gacggtagta ctttagcgta ctggggccag gggacccagg
tcaccgtctc ctcaagccca 840aatcttgtga caaaactcac acatgcccac
cgtgcccagc acctgaactc ctggggggac 900cgtcagtctt cctcttcccc
ccaaaaccca aggacaccct catgatctcc cggacccctg 960aggtcacatg
cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt
1020acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag
cagtacaaca 1080gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca
ggactggctg aatggcaagg 1140agtacaagtg caaggtctcc aacaaagccc
tcccagcccc catcgagaaa accatctcca 1200aagccaaagg gcagccccga
gaaccacagg tgtacaccct gcccccatcc cgggatgagc 1260tgaccaagaa
ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg
1320ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg
cctcccgtgc 1380tggactccga cggctccttc ttcctctaca gcaagctcac
cgtggacaag agcaggtggc 1440agcaggggaa cgtcttctca tgctccgtga
tgcatgaggc tctgcacaac cactacacgc 1500agaagagcct ctccctgtct
ccgggtaaat ga 15325622PRTArtificial sequenceNanobody construct 5Lys
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Gly Phe Asn
20 25 30Asp Met Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
Val 35 40 45Ala Leu Ile Ser Arg Val Gly Val Thr Ser Ser Ala Asp Ser
Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Val Asn Ala Lys Asp Thr
Val Tyr Leu65 70 75 80Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala
Val Tyr Tyr Cys Tyr 85 90 95Met Asp Gln Arg Leu Asp Gly Ser Thr Leu
Ala Tyr Trp Gly Gln Gly 100 105 110Thr Gln Val Thr Val Ser Ser Gly
Gly Gly Gly Ser Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Glu Val Gln Leu Val Glu145 150 155 160Ser
Gly Gly Ser Leu Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys 165 170
175Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr Ala Met Ser Trp Val Arg
180 185 190Gln Val Pro Gly Lys Gly Leu Glu Trp Val Ser Ser Ile Asn
Trp Ser 195 200 205Gly Thr His Thr Asp Tyr Ala Asp Ser Val Lys Gly
Arg Phe Thr Ile 210 215 220Ser Arg Asn Asn Ala Asn Asn Thr Leu Tyr
Leu Gln Met Asn Ser Leu225 230 235 240Lys Ser Glu Asp Thr Ala Val
Tyr Tyr Cys Ala Lys Asn Trp Arg Asp 245 250 255Ala Gly Thr Thr Trp
Phe Glu Lys Ser Gly Ser Ala Gly Gln Gly Thr 260 265 270Gln Val Thr
Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly 275 280 285Gly
Ser Val Asp Asn Lys Thr Phe Ser Val Cys Ser Arg Asp Phe Thr 290 295
300Pro Pro Thr Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly
His305 310 315 320Phe Pro Pro Thr Ile Gln Leu Leu Cys Leu Val Ser
Gly Tyr Thr Pro 325 330 335Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp
Gly Gln Val Met Asp Val 340 345 350Asp Leu Ser Thr Ala Ser Thr Thr
Gln Glu Gly Glu Leu Ala Ser Thr 355 360 365Gln Ser Glu Leu Thr Leu
Ser Gln Lys His Trp Leu Ser Asp Arg Thr 370 375 380Tyr Thr Cys Gln
Val Thr Tyr Gln Gly His Thr Phe Glu Asp Ser Thr385 390 395 400Lys
Lys Cys Ala Asp Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser 405 410
415Arg Pro Ser Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr
420 425 430Cys Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn
Leu Thr 435 440 445Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser
Thr Arg Lys Glu 450 455 460Glu Lys Gln Arg Asn Gly Thr Leu Thr Val
Thr Ser Thr Leu Pro Val465 470 475 480Gly Thr Arg Asp Trp Ile Glu
Gly Glu Thr Tyr Gln Cys Arg Val Thr 485 490 495His Pro His Leu Pro
Arg Ala Leu Met Arg Ser Thr Thr Lys Thr Ser 500 505 510Gly Pro Arg
Ala Ala Pro Glu Val Tyr Ala Phe Ala Thr Pro Glu Trp 515 520 525Pro
Gly Ser Arg Asp Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe 530 535
540Met Pro Glu Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln
Leu545 550 555 560Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys
Thr Lys Gly Ser 565 570 575Gly Phe Phe Val Phe Ser Arg Leu Glu Val
Thr Arg Ala Glu Trp Glu 580 585 590Gln Lys Asp Glu Phe Ile Cys Arg
Ala Val His Glu Ala Ala Ser Pro 595 600 605Ser Gln Thr Val Gln Arg
Ala Val Ser Val Asn Pro Gly Lys 610 615 62061869DNAArtificial
sequenceNanobody construct 6aaggtgcagc tggtggagtc tgggggaggc
ttggtgcagc ctggggggtc tctgagactc 60tcctgtgcag cctctggaag catcttcggt
ttcaatgaca tggcctggta ccgccaggct 120ccagggaagc agcgcgagtt
ggtcgcacta attagtaggg ttggtgtcac aagttctgca 180gactccgtga
agggccgatt caccatctcc agagtcaacg ccaaggacac ggtgtatctg
240caaatgaaca gcctgaaacc tgaggatacg gccgtctatt attgttatat
ggatcagcga 300ctcgacggta gtactttagc gtactggggc caggggaccc
aggtcaccgt atcgagtggg 360ggcgggggaa gtggcggagg tgggtccggt
ggcggaggca gcggtggagg aggtagtggc 420ggtggcggta gtggcggtgg
cggcagtgga ggcggaggat ccgaagtgca gttagtcgag 480tcagggggta
gcttggtgca gccggggggt agcctgcgcc tgagctgcgc cgcgagcggc
540ttcaccttcg acgattatgc gatgtcatgg gtcagacagg tccctggtaa
agggcttgaa 600tgggtttcct caataaactg gagcggcacc catacggatt
atgcggatag cgtgaaagga 660cgttttacca ttagccgcaa taacgctaat
aacactctgt acctacaaat gaactcgctc 720aaatctgaag atactgctgt
ctactattgt gccaagaatt ggcgtgacgc agggaccaca 780tggtttgaga
aatccggtag cgcgggccaa ggcactcagg tgacagtgag cagcggcggc
840ggcagcggcg gcggcagcgg cggcggcagc gtcgacaaca aaaccttcag
cgtctgctcc 900agggacttca ccccgcccac cgtgaagatc ttacagtcgt
cctgcgacgg cggcgggcac 960ttccccccga ccatccagct cctgtgcctc
gtctctgggt acaccccagg gactatcaac 1020atcacctggc tggaggacgg
gcaggtcatg gacgtggact tgtccaccgc ctctaccacg 1080caggagggtg
agctggcctc cacacaaagc gagctcaccc tcagccagaa gcactggctg
1140tcagaccgca cctacacctg ccaggtcacc tatcaaggtc acacctttga
ggacagcacc 1200aagaagtgtg cagattccaa cccgagaggg gtgagcgcct
acctaagccg gcccagcccg 1260ttcgacctgt tcatccgcaa gtcgcccacg
atcacctgtc tggtggtgga cctggcaccc 1320agcaagggga ccgtgaacct
gacctggtcc cgggccagtg ggaagcctgt gaaccactcc 1380accagaaagg
aggagaagca gcgcaatggc acgttaaccg tcacgtccac cctgccggtg
1440ggcacccgag actggatcga gggggagacc taccagtgca gggtgaccca
cccccacctg 1500cccagggccc tcatgcggtc cacgaccaag accagcggcc
cgcgtgctgc cccggaagtc 1560tatgcgtttg cgacgccgga gtggccgggg
agccgggaca agcgcaccct cgcctgcctg 1620atccagaact tcatgcctga
ggacatctcg gtgcagtggc tgcacaacga ggtgcagctc
1680ccggacgccc ggcacagcac gacgcagccc cgcaagacca agggctccgg
cttcttcgtc 1740ttcagccgcc tggaggtgac cagggccgaa tgggagcaga
aagatgagtt catctgccgt 1800gcagtccatg aggcagcgag cccctcacag
accgtccagc gagcggtgtc tgtaaatccc 1860ggtaaatga
18697622PRTArtificial sequenceNanobody construct 7Glu Val Gln Leu
Val Glu Ser Gly Gly Ser Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 20 25 30Ala Met
Ser Trp Val Arg Gln Val Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Ser Ile Asn Trp Ser Gly Thr His Thr Asp Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asn Asn Ala Asn Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Lys Asn Trp Arg Asp Ala Gly Thr Thr Trp Phe Glu Lys
Ser Gly 100 105 110Ser Ala Gly Gln Gly Thr Gln Val Thr Val Ser Ser
Gly Gly Gly Gly 115 120 125Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser 130 135 140Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Glu145 150 155 160Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Ser 165 170 175Leu Arg Leu
Ser Cys Ala Ala Ser Gly Ser Ile Phe Gly Phe Asn Asp 180 185 190Met
Ala Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala 195 200
205Leu Ile Ser Arg Val Gly Val Thr Ser Ser Ala Asp Ser Val Lys Gly
210 215 220Arg Phe Thr Ile Ser Arg Val Asn Ala Lys Asp Thr Val Tyr
Leu Gln225 230 235 240Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val
Tyr Tyr Cys Tyr Met 245 250 255Asp Gln Arg Leu Asp Gly Ser Thr Leu
Ala Tyr Trp Gly Gln Gly Thr 260 265 270Gln Val Thr Val Ser Ser Gly
Gly Gly Ser Gly Gly Gly Ser Gly Gly 275 280 285Gly Ser Val Asp Asn
Lys Thr Phe Ser Val Cys Ser Arg Asp Phe Thr 290 295 300Pro Pro Thr
Val Lys Ile Leu Gln Ser Ser Cys Asp Gly Gly Gly His305 310 315
320Phe Pro Pro Thr Ile Gln Leu Leu Cys Leu Val Ser Gly Tyr Thr Pro
325 330 335Gly Thr Ile Asn Ile Thr Trp Leu Glu Asp Gly Gln Val Met
Asp Val 340 345 350Asp Leu Ser Thr Ala Ser Thr Thr Gln Glu Gly Glu
Leu Ala Ser Thr 355 360 365Gln Ser Glu Leu Thr Leu Ser Gln Lys His
Trp Leu Ser Asp Arg Thr 370 375 380Tyr Thr Cys Gln Val Thr Tyr Gln
Gly His Thr Phe Glu Asp Ser Thr385 390 395 400Lys Lys Cys Ala Asp
Ser Asn Pro Arg Gly Val Ser Ala Tyr Leu Ser 405 410 415Arg Pro Ser
Pro Phe Asp Leu Phe Ile Arg Lys Ser Pro Thr Ile Thr 420 425 430Cys
Leu Val Val Asp Leu Ala Pro Ser Lys Gly Thr Val Asn Leu Thr 435 440
445Trp Ser Arg Ala Ser Gly Lys Pro Val Asn His Ser Thr Arg Lys Glu
450 455 460Glu Lys Gln Arg Asn Gly Thr Leu Thr Val Thr Ser Thr Leu
Pro Val465 470 475 480Gly Thr Arg Asp Trp Ile Glu Gly Glu Thr Tyr
Gln Cys Arg Val Thr 485 490 495His Pro His Leu Pro Arg Ala Leu Met
Arg Ser Thr Thr Lys Thr Ser 500 505 510Gly Pro Arg Ala Ala Pro Glu
Val Tyr Ala Phe Ala Thr Pro Glu Trp 515 520 525Pro Gly Ser Arg Asp
Lys Arg Thr Leu Ala Cys Leu Ile Gln Asn Phe 530 535 540Met Pro Glu
Asp Ile Ser Val Gln Trp Leu His Asn Glu Val Gln Leu545 550 555
560Pro Asp Ala Arg His Ser Thr Thr Gln Pro Arg Lys Thr Lys Gly Ser
565 570 575Gly Phe Phe Val Phe Ser Arg Leu Glu Val Thr Arg Ala Glu
Trp Glu 580 585 590Gln Lys Asp Glu Phe Ile Cys Arg Ala Val His Glu
Ala Ala Ser Pro 595 600 605Ser Gln Thr Val Gln Arg Ala Val Ser Val
Asn Pro Gly Lys 610 615 62081869DNAArtificial sequenceNanobody
construct 8gaggtgcagc tggtggagtc tgggggctcc ttggtgcagc ctggggggtc
tctgagactc 60tcctgtgcag cctctggctt cacttttgat gattatgcca tgagctgggt
ccgacaggtt 120ccagggaagg ggttggagtg ggtttcatct attaattggt
ctggtactca cacagactat 180gcagactccg tgaagggccg attcaccatc
tccagaaaca acgccaataa cacgctgtat 240ctacaaatga acagtctgaa
atctgaggac acggccgtgt attactgtgc aaaaaactgg 300agagacgcag
gtactacctg gttcgaaaag tccggctccg cgggccaggg gacccaggtc
360accgtatcga gtgggggcgg gggaagtggc ggaggtgggt ccggtggcgg
aggcagcggt 420ggaggaggta gtggcggtgg cggtagtggc ggtggcggca
gtggaggcgg aggatccgag 480gtgcagctgg tggagtctgg gggaggcttg
gtgcagcctg gggggtctct gagactctcc 540tgtgcagcct ctggaagcat
cttcggtttc aatgacatgg cctggtaccg ccaggctcca 600gggaagcagc
gcgagttggt cgcactaatt agtagggttg gtgtcacaag ttctgcagac
660tccgtgaagg gccgattcac catctccaga gtcaacgcca aggacacggt
gtatctgcaa 720atgaacagcc tgaaacctga ggatacggcc gtctattatt
gttatatgga tcagcgactc 780gacggtagta ctttagcgta ctggggccag
gggacccagg tcaccgtctc ctcaggcggc 840ggcagcggcg gcggcagcgg
cggcggcagc gtcgacaaca aaaccttcag cgtctgctcc 900agggacttca
ccccgcccac cgtgaagatc ttacagtcgt cctgcgacgg cggcgggcac
960ttccccccga ccatccagct cctgtgcctc gtctctgggt acaccccagg
gactatcaac 1020atcacctggc tggaggacgg gcaggtcatg gacgtggact
tgtccaccgc ctctaccacg 1080caggagggtg agctggcctc cacacaaagc
gagctcaccc tcagccagaa gcactggctg 1140tcagaccgca cctacacctg
ccaggtcacc tatcaaggtc acacctttga ggacagcacc 1200aagaagtgtg
cagattccaa cccgagaggg gtgagcgcct acctaagccg gcccagcccg
1260ttcgacctgt tcatccgcaa gtcgcccacg atcacctgtc tggtggtgga
cctggcaccc 1320agcaagggga ccgtgaacct gacctggtcc cgggccagtg
ggaagcctgt gaaccactcc 1380accagaaagg aggagaagca gcgcaatggc
acgttaaccg tcacgtccac cctgccggtg 1440ggcacccgag actggatcga
gggggagacc taccagtgca gggtgaccca cccccacctg 1500cccagggccc
tcatgcggtc cacgaccaag accagcggcc cgcgtgctgc cccggaagtc
1560tatgcgtttg cgacgccgga gtggccgggg agccgggaca agcgcaccct
cgcctgcctg 1620atccagaact tcatgcctga ggacatctcg gtgcagtggc
tgcacaacga ggtgcagctc 1680ccggacgccc ggcacagcac gacgcagccc
cgcaagacca agggctccgg cttcttcgtc 1740ttcagccgcc tggaggtgac
cagggccgaa tgggagcaga aagatgagtt catctgccgt 1800gcagtccatg
aggcagcgag cccctcacag accgtccagc gagcggtgtc tgtaaatccc
1860ggtaaatga 18699525PRTArtificial sequenceNanobody construct 9Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Asn Phe Asn
20 25 30Tyr Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe
Val 35 40 45Ala Ala Ile Arg Trp Ser Gly Ser Ser Thr Tyr Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn
Thr Val Ala65 70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr
Ala Ile Tyr Tyr Cys 85 90 95Ala Leu Arg Lys Gly Ile Pro Tyr Ser Thr
Ser Asp Arg Val Ile Lys 100 105 110Gly Val Asn Asp Tyr Asp Tyr Trp
Gly Gln Gly Thr Gln Val Thr Val 115 120 125Ser Ser Gly Gly Gly Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly
Gly Gly Gly Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170
175Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Ile Ala Ser Gly Leu
180 185 190Pro Phe Ser Thr Lys Ser Met Gly Trp Phe Arg Gln Ala Pro
Gly Lys 195 200 205Glu Arg Glu Phe Val Ala Arg Ile Ser Pro Gly Gly
Thr Ser Arg Tyr 210 215 220Tyr Gly Asp Phe Val Lys Gly Arg Phe Ala
Ile Ser Arg Asp Asn Ala225 230 235 240Lys Asn Thr Thr Trp Leu Gln
Met Asn Ser Leu Lys Ala Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys
Ala Ser Gly Glu Arg Ser Thr Tyr Ile Gly Ser 260 265 270Asn Tyr Tyr
Arg Thr Asn Glu Tyr Asp Tyr Trp Gly Thr Gly Thr Gln 275 280 285Val
Thr Val Ser Ser Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys 290 295
300Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe
Leu305 310 315 320Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser
Arg Thr Pro Glu 325 330 335Val Thr Cys Val Val Val Asp Val Ser His
Glu Asp Pro Glu Val Lys 340 345 350Phe Asn Trp Tyr Val Asp Gly Val
Glu Val His Asn Ala Lys Thr Lys 355 360 365Pro Arg Glu Glu Gln Tyr
Asn Ser Thr Tyr Arg Val Val Ser Val Leu 370 375 380Thr Val Leu His
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys385 390 395 400Val
Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys 405 410
415Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
420 425 430Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
Val Lys 435 440 445Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu
Ser Asn Gly Gln 450 455 460Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
Val Leu Asp Ser Asp Gly465 470 475 480Ser Phe Phe Leu Tyr Ser Lys
Leu Thr Val Asp Lys Ser Arg Trp Gln 485 490 495Gln Gly Asn Val Phe
Ser Cys Ser Val Met His Glu Ala Leu His Asn 500 505 510His Tyr Thr
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 515 520
52510523PRTArtificial sequenceNanobody construct 10Glu Val Gln Leu
Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Ala Ser Gly Ser Ile Phe Asn Phe Asn 20 25 30Tyr Met
Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val 35 40 45Ala
Ala Ile Arg Trp Ser Gly Ser Ser Thr Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ala Lys Asn Thr Val Ala65
70 75 80Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Ile Tyr Tyr
Cys 85 90 95Ala Leu Arg Lys Gly Ile Pro Tyr Ser Thr Ser Asp Arg Val
Ile Lys 100 105 110Gly Val Asn Asp Tyr Asp Tyr Trp Gly Gln Gly Thr
Gln Val Thr Val 115 120 125Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly
Gly Ser Gly Gly Gly Gly 130 135 140Ser Gly Gly Gly Gly Ser Gly Gly
Gly Gly Ser Gly Gly Gly Gly Ser145 150 155 160Gly Gly Gly Gly Ser
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu 165 170 175Val Gln Ala
Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg 180 185 190Thr
Phe Asn Thr Tyr Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys 195 200
205Glu Arg Glu Phe Val Ala Ala Asn Asn Trp Ser Gly Gly Ala Thr Ser
210 215 220Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala225 230 235 240Lys Asn Thr Val Phe Leu Gln Met Asn Thr Leu
Lys Pro Glu Asp Thr 245 250 255Ala Val Tyr Tyr Cys Ala Ala Ala Asp
Arg Gly Gly Gly Trp Leu Val 260 265 270Val Arg Glu Asn Asp Tyr Asp
Tyr Trp Gly Gln Gly Thr Gln Val Thr 275 280 285Val Ser Ser Glu Pro
Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro 290 295 300Cys Pro Ala
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro305 310 315
320Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr
325 330 335Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
Phe Asn 340 345 350Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
Thr Lys Pro Arg 355 360 365Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val
Val Ser Val Leu Thr Val 370 375 380Leu His Gln Asp Trp Leu Asn Gly
Lys Glu Tyr Lys Cys Lys Val Ser385 390 395 400Asn Lys Ala Leu Pro
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys 405 410 415Gly Gln Pro
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp 420 425 430Glu
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe 435 440
445Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu
450 455 460Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
Ser Phe465 470 475 480Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
Arg Trp Gln Gln Gly 485 490 495Asn Val Phe Ser Cys Ser Val Met His
Glu Ala Leu His Asn His Tyr 500 505 510Thr Gln Lys Ser Leu Ser Leu
Ser Pro Gly Lys 515 52011518PRTArtificial sequenceNanobody
construct 11Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Val Ala Ser Gly Arg Thr Phe
Asn Thr Tyr 20 25 30Gly Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu
Arg Glu Phe Val 35 40 45Ala Ala Asn Asn Trp Ser Gly Gly Ala Thr Ser
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Thr Val Phe65 70 75 80Leu Gln Met Asn Thr Leu Lys Pro
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Ala Ala Asp Arg Gly Gly
Gly Trp Leu Val Val Arg Glu Asn Asp 100 105 110Tyr Asp Tyr Trp Gly
Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly 115 120 125Gly Gly Ser
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 130 135 140Gly
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly145 150
155 160Ser Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala
Gly 165 170 175Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr
Phe Glu Gly 180 185 190Asn Pro Met Gly Trp Phe Arg Gln Ala Ser Gly
Lys Lys Arg Glu Phe 195 200 205Val Ala Ser Ile Asp Trp Ser Gly Gly
Ile Thr Ser Tyr Ala Asp Ser 210 215 220Val Lys Gly Arg Phe Thr Ile
Ser Arg Asp Asn Ala Lys Asn Thr Val225 230 235 240Tyr Leu Gln Met
Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr 245 250 255Cys Ala
Ala Ser Ala Arg Phe Gly Ser Gly Ser Tyr Tyr Asp Leu Met 260 265
270Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Glu Pro
275 280 285Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
Pro Glu 290 295 300Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp305 310 315 320Thr Leu Met Ile Ser Arg Thr Pro Glu
Val Thr Cys Val Val Val Asp 325 330 335Val Ser His Glu Asp Pro Glu
Val Lys Phe Asn Trp Tyr Val Asp Gly 340 345 350Val Glu Val His Asn
Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 355 360 365Ser Thr Tyr
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 370 375 380Leu
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro385 390
395 400Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg
Glu 405 410 415Pro Gln Val
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 420 425 430Gln
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 435 440
445Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
450 455 460Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
Ser Lys465 470 475 480Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly
Asn Val Phe Ser Cys 485 490 495Ser Val Met His Glu Ala Leu His Asn
His Tyr Thr Gln Lys Ser Leu 500 505 510Ser Leu Ser Pro Gly Lys
51512330DNAHomo sapiens 12cacctgaact cctgggggga ccgtcagtct
tcctcttccc cccaaaaccc aaggacaccc 60tcatgatctc ccggacccct gaggtcacat
gcgtggtggt ggacgtgagc cacgaagacc 120ctgaggtcaa gttcaactgg
tacgtggacg gcgtggaggt gcataatgcc aagacaaagc 180cgcgggagga
gcagtacaac agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc
240aggactggct gaatggcaag gagtacaagt gcaaggtctc caacaaagcc
ctcccagccc 300ccatcgagaa aaccatctcc aaagccaaag 33013323DNAHomo
sapiens 13ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag
ctgaccaaga 60accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc
gccgtggagt 120gggagagcaa tgggcagccg gagaacaact acaagaccac
gcctcccgtg ctggactccg 180acggctcctt cttcctctac agcaagctca
ccgtggacaa gagcaggtgg cagcagggga 240acgtcttctc atgctccgtg
atgcatgagg ctctgcacaa ccactacacg cagaagagcc 300tctccctgtc
tccgggtaaa tga 3231445DNACamelidae 14agcccaaatc ttgtgacaaa
actcacacat gcccaccgtg cccag 45
* * * * *